US20080269112A1 - Antineoplastic Agents Targeted via Glut Transporters - Google Patents
Antineoplastic Agents Targeted via Glut Transporters Download PDFInfo
- Publication number
- US20080269112A1 US20080269112A1 US12/027,014 US2701408A US2008269112A1 US 20080269112 A1 US20080269112 A1 US 20080269112A1 US 2701408 A US2701408 A US 2701408A US 2008269112 A1 US2008269112 A1 US 2008269112A1
- Authority
- US
- United States
- Prior art keywords
- tumor
- conjugate
- pyro
- glucose
- irradiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940034982 antineoplastic agent Drugs 0.000 title abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 59
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims description 44
- 239000003504 photosensitizing agent Substances 0.000 claims description 20
- JUDGRMABQJKRPW-XIADSQHASA-N CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C Chemical compound CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C JUDGRMABQJKRPW-XIADSQHASA-N 0.000 claims description 13
- 210000004185 liver Anatomy 0.000 claims description 13
- 125000005647 linker group Chemical group 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 230000002381 testicular Effects 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 38
- 239000003814 drug Substances 0.000 abstract description 19
- 229940124597 therapeutic agent Drugs 0.000 abstract description 14
- 229940039227 diagnostic agent Drugs 0.000 abstract description 11
- 239000000032 diagnostic agent Substances 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000002428 photodynamic therapy Methods 0.000 description 36
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 29
- 239000000203 mixture Substances 0.000 description 26
- 208000032612 Glial tumor Diseases 0.000 description 25
- 206010018338 Glioma Diseases 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 108091052347 Glucose transporter family Proteins 0.000 description 23
- 238000003384 imaging method Methods 0.000 description 23
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 22
- 102000042092 Glucose transporter family Human genes 0.000 description 21
- 239000002904 solvent Substances 0.000 description 19
- -1 succinimidyl esters Chemical class 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000004807 localization Effects 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 17
- 239000000975 dye Substances 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000012300 argon atmosphere Substances 0.000 description 11
- 239000002872 contrast media Substances 0.000 description 11
- 150000002540 isothiocyanates Chemical class 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000003470 mitochondria Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- POPDQJMNXQQAII-UWJYYQICSA-N methyl 3-[(22S,23S)-17-ethenyl-12-ethyl-13,18,22,27-tetramethyl-3,5-dioxo-4-oxa-8,24,25,26-tetrazahexacyclo[19.2.1.16,9.111,14.116,19.02,7]heptacosa-1,6,9(27),10,12,14(26),15,17,19(25),20-decaen-23-yl]propanoate Chemical compound CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(=O)OC)[C@@H]4C)c4c5[nH]c(cc1n2)c(C)c5c(=O)oc4=O)c(C)c3C=C POPDQJMNXQQAII-UWJYYQICSA-N 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000000799 fluorescence microscopy Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 230000004190 glucose uptake Effects 0.000 description 7
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 7
- 229960004657 indocyanine green Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012634 optical imaging Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 150000002303 glucose derivatives Chemical class 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 150000004032 porphyrins Chemical class 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 102000005548 Hexokinase Human genes 0.000 description 5
- 108700040460 Hexokinases Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 5
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- XZSVAMUZTKNGDN-JBRJOJLESA-L bacteriochlorophylls Chemical compound [Mg+2].[N-]1C2=C(C=3C(C(C)C(=CC=4C(=C(C(C)=O)C(=C5)N=4)C)N=3)CCC(=O)OC\C=C(/C)CCCC(C)CCCC(C)CCCC(C)C)C(C(=O)OC)C([O-])=C2C(C)=C1C=C1C(CC)C(C)C5=N1 XZSVAMUZTKNGDN-JBRJOJLESA-L 0.000 description 4
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 238000012632 fluorescent imaging Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 108010057573 Flavoproteins Proteins 0.000 description 3
- 102000003983 Flavoproteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000006377 glucose transport Effects 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 150000003949 imides Chemical group 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000886 photobiology Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 0 *#IC1C(O)OC(CO)C2C1*2 Chemical compound *#IC1C(O)OC(CO)C2C1*2 0.000 description 2
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical class CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 description 2
- FDKRLXBXYZKWRZ-UWJYYQICSA-N 3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(CC(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)O)C4=N3)O)C)C FDKRLXBXYZKWRZ-UWJYYQICSA-N 0.000 description 2
- DDGWQKBAJKJDQR-HYRLUJJGSA-O 3-[(2z)-2-[(2e,4e,6e)-7-[1,1-dimethyl-3-[3-oxo-3-[[(3s,5r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]amino]propyl]benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]-n-[(3s,5r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]p Chemical compound N([C@H]1C([C@@H](O)C(CO)OC1O)O)C(=O)CCN1C2=CC=C3C=CC=CC3=C2C(C)(C)\C1=C\C=C\C=C\C=C\C(C(C1=C2C=CC=CC2=CC=C11)(C)C)=[N+]1CCC(=O)N[C@@H]1C(O)OC(CO)[C@H](O)C1O DDGWQKBAJKJDQR-HYRLUJJGSA-O 0.000 description 2
- GRAVJJAQKJDGPM-UHFFFAOYSA-N 3-[2-[7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoic acid;bromide Chemical compound [Br-].OC(=O)CCN1C2=CC=C3C=CC=CC3=C2C(C)(C)\C1=C/C=C/C=C/C=C/C1=[N+](CCC(O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C GRAVJJAQKJDGPM-UHFFFAOYSA-N 0.000 description 2
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 2
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YVJXTNFYGMZWPR-UHFFFAOYSA-N CC1C(O)OC(CO)C(O)C1O Chemical compound CC1C(O)OC(CO)C(O)C1O YVJXTNFYGMZWPR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 2
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- IWKYEJKHXKRZIJ-UIYBDNSESA-N Methyl pheophorbide a Natural products CCC1=C(C)\C2=C\c3[nH]c(\C=C4/N=C([C@@H](CCC(=O)OC)[C@@H]4C)C4=c5[nH]c(=CC1=N2)c(C)c5C(=O)[C@@H]4C(=O)OC)c(C)c3C=C IWKYEJKHXKRZIJ-UIYBDNSESA-N 0.000 description 2
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 150000004036 bacteriochlorins Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 2
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000020937 fasting conditions Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HUXSMOZWPXDRTN-SDHKEVEOSA-N methyl (3R,21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-22-(3-methoxy-3-oxopropyl)-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaene-3-carboxylate Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C([C@@H](C(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OC)C4=N3)C(=O)OC)O)C)C HUXSMOZWPXDRTN-SDHKEVEOSA-N 0.000 description 2
- HUXSMOZWPXDRTN-UHFFFAOYSA-N methyl 16-ethenyl-11-ethyl-4-hydroxy-22-(3-methoxy-3-oxopropyl)-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaene-3-carboxylate Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(C(C(=C5C(C(C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OC)C4=N3)C(=O)OC)O)C)C HUXSMOZWPXDRTN-UHFFFAOYSA-N 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 108010013121 palladium-bacteriopheophorbide Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DEPMSUUWSGUYKQ-IWXIMVSXSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CNC1=CC=C([N+]([O-])=O)C2=NON=C12 DEPMSUUWSGUYKQ-IWXIMVSXSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- SHZGCJCMOBCMKK-QYESYBIKSA-N 6-deoxyglucose Chemical class C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-QYESYBIKSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 108010070075 Bacteriochlorophyll A Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- PTPSBTZNKBQBKH-XLODUFHSSA-O O=C1CCC(=O)N1O.[2H]C#C.[Cl-].[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)NC1C(O)OC(CO)C(O)C1O.[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)O.[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)ON1C(=O)CCC1=O.[NH3+]C1C(O)OC(CO)C(O)C1O Chemical compound O=C1CCC(=O)N1O.[2H]C#C.[Cl-].[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)NC1C(O)OC(CO)C(O)C1O.[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)O.[H][C@@]1(C)C2=N/C(=C3/CC(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)ON1C(=O)CCC1=O.[NH3+]C1C(O)OC(CO)C(O)C1O PTPSBTZNKBQBKH-XLODUFHSSA-O 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101150116689 Slc2a2 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MWXKLIWJHSFRTB-LLCVXGSRSA-N [H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCN=C=S)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C(C)=O)[C@]([H])(C)[C@@]3([H])CC)[C@@]1([H])CCC(=O)OC.[H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCNC(=S)NC4C(O)OC(CO)C(O)C4O)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C(C)=O)[C@]([H])(C)[C@@]3([H])CC)[C@@]1([H])CCC(=O)OC Chemical compound [H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCN=C=S)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C(C)=O)[C@]([H])(C)[C@@]3([H])CC)[C@@]1([H])CCC(=O)OC.[H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCNC(=S)NC4C(O)OC(CO)C(O)C4O)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C(C)=O)[C@]([H])(C)[C@@]3([H])CC)[C@@]1([H])CCC(=O)OC MWXKLIWJHSFRTB-LLCVXGSRSA-N 0.000 description 1
- BZXKFOFJLISREK-LNOJGCKTSA-N [H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCN=C=S)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)OC.[H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCNC(=S)NC4C(O)OC(CO)C(O)C4O)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)OC Chemical compound [H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCN=C=S)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)OC.[H][C@@]1(C)C2=N/C(=C3/C(=O)N(CCCNC(=S)NC4C(O)OC(CO)C(O)C4O)C(=O)C4=C3NC(=C4C)/C=C3\N=C(/C=C4\N/C(=C\2)C(C)=C4C=C)C(C)=C3CC)[C@@]1([H])CCC(=O)OC BZXKFOFJLISREK-LNOJGCKTSA-N 0.000 description 1
- IAKNZWPCZACGLA-NUOSDLBCSA-N [H][C@@]1(CCC(=O)OC)C2=N/C(=C\C3=C(C)C(C(C)=O)=C(/C=C4\N=C(/C=C5\N/C(=C\2CC(=O)OC)C(C(=O)NCCCN=C=S)=C5C)[C@]([H])(CC)[C@@]4([H])C)N3)[C@@]1([H])C.[H][C@@]1(CCC(=O)OC)C2=N/C(=C\C3=C(C)C(C(C)=O)=C(/C=C4\N=C(/C=C5\N/C(=C\2CC(=O)OC)C(C(=O)NCCCNC(=S)NC2C(O)OC(CO)C(O)C2O)=C5C)[C@]([H])(CC)[C@@]4([H])C)N3)[C@@]1([H])C Chemical compound [H][C@@]1(CCC(=O)OC)C2=N/C(=C\C3=C(C)C(C(C)=O)=C(/C=C4\N=C(/C=C5\N/C(=C\2CC(=O)OC)C(C(=O)NCCCN=C=S)=C5C)[C@]([H])(CC)[C@@]4([H])C)N3)[C@@]1([H])C.[H][C@@]1(CCC(=O)OC)C2=N/C(=C\C3=C(C)C(C(C)=O)=C(/C=C4\N=C(/C=C5\N/C(=C\2CC(=O)OC)C(C(=O)NCCCNC(=S)NC2C(O)OC(CO)C(O)C2O)=C5C)[C@]([H])(CC)[C@@]4([H])C)N3)[C@@]1([H])C IAKNZWPCZACGLA-NUOSDLBCSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- FCVPQJRQZFMXTM-UHFFFAOYSA-N amino thiocyanate Chemical compound NSC#N FCVPQJRQZFMXTM-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002991 anti-hyperkinetic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940124344 antianaemic agent Drugs 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- XBZPNDFVHSASSD-UHFFFAOYSA-N ethanol;propane-1,2,3-triol;hydrate Chemical compound O.CCO.OCC(O)CO XBZPNDFVHSASSD-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000003166 hypermetabolic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000001189 phytyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- COWCVGUYIYQWPC-MRZQNBKKSA-N purpurin 18 Chemical compound N1C(C=C2C(=C(CC)C(C=C3C(=C4C(=C5C(=O)OC4=O)N3)C)=N2)C)=C(C=C)C(C)=C1C=C1C(C)C(CCC(=O)OCC(/C)=C/CCC(C)CCCC(C)CCCC(C)CC)C5=N1 COWCVGUYIYQWPC-MRZQNBKKSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
Definitions
- the invention is in the field of antineoplastic agents and cancer diagnostic agents. More particularly, the invention pertains to novel 2-deoxyglucose conjugates, their use and methods of making such compounds.
- 18 FDG is an analog of glucose that enters cells via glucose transporters (GLUT) and is phosphorylated to 18 FDG-6-phosphate by hexokinase, the first enzyme in the glycolytic pathway.
- This enzyme converts glucose, 2-deoxyglucose or 18 FDG from a neutral, membrane-permeable form to an anionic, membrane-impermeable form. Reversal of this reaction requires glucose-6-phosphatase, which is generally not present at high enough concentration in most cells to mediate this reaction.
- Further metabolism of 18 FDG-6-phosphate by phosphoglucose isomerase, the next enzyme in the glycolytic pathway, or by enzymes in the glycogen or pentose shunt pathways does not occur (Pauwels, E.
- Speizer in 1985 (Speizer, L., Haugland, R., and Kutchai, H. (1985) Asymmetric transport of a fluorescent glucose analogue by human erythrocytes. Biochim. Biophys. Acta 815, 75-84), exploited the glucose transport pathway to deliver a fluorescent analog of glucose, 6-deoxy-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-aminoglucose, into human erythrocytes. This analog is a derivative of 6-deoxyglucose containing a fluorophore on the 6-position.
- U.S. Pat. No. 6,489,302 relates to a conjugate, comprising a saccharide and one or more therapeutic or diagnostic agents for treatment and diagnosis of cancer and viral disease which uses the GLUT pathway.
- NIR Near-infrared
- a key limitation of cancer drugs is their lack of specificity for tumor cells. There is therefore a need to develop tumor-specific agents that are targeted at GLUT transporters, which constitute the main pathway that tumor cells utilize for import of substrates for energy production. Since glucose is the principal substrate for energy production utilized by most if not all tumors the agents which target this critical pathway should exhibit a substantially enhanced level of tumor specificity.
- Stable bacteriochlorophyll (BChl) analogs derived from R. Sphaeroides are excellent NIR dyes for NIRF and PDT because of their favorable photophysical properties ( 1 O 2 yield: 45%) and long activation and fluorescence emission wavelengths (750-850 nm).
- PChl Stable bacteriochlorophyll
- target-specific BChls derived from stable BChl suitable by bioconjugation are desired.
- a universal linker introduced into a stable BChl molecule that will facilitate binding of biomolecules such as peptides, proteins, and other affinity ligands is desirable.
- the present invention provides synthesis of novel functionalized BChl dyes containing an isothiocyanate moiety, their bioconjugation to cancer targeting agents, and the in vivo optical imaging of animal tumors with these new bioconjugates.
- the present invention relates to novel chemical compounds, referred to herein as 2-deoxyglucose conjugates or pharmaceutically acceptable salts thereof, in which a 2-deoxyglucose conjugate is represented by the formula:
- L is a linker group; and D is a diagnostic or therapeutic agent, provided that said conjugate is not [ 18 F]deoxyglucose or 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose.
- the present invention provides methods of making the novel chemical compounds of the present invention.
- the present invention also relates to pharmaceutical and veterinary compositions comprising one or more of the 2-deoxyglucose conjugates of the present invention, and one or more pharmaceutically acceptable diluents, carriers or excipients.
- the invention further relates to a method of treating tumor disease in an animal, comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof to treat the tumor disease of the animal.
- FIG. 1 Fluorescence images of drug control (top row: tumor+Pyro-2DG), normal tissue control (middle row: normal tissue of the same animal) and tumor control (bottom row, tumor alone) in 9L glioma bearing animals. Note: The tumor and normal muscle margin are outlined with a black circle in the redox ratio images (the first column), the redox ratio histograms corresponding to the marked region (black circle) are also presented here (the second column).
- FIG. 2 Selective tumor destruction by PDT corresponds to a marked change in the intrinsic fluorescence of tumors (decreased NADH, increased FP) and the selective photobleaching of Pyro-2DG.
- Top row PDT of tumor with Pyro-2DG; bottom row: light control, PDT of tumor without Pyro-2DG).
- the irradiated region is marked as a white cross, and the tumor margin is outlined with a black circle in both experiments.
- FIG. 3 Confocal microscopy images of 9L glioma cells incubated with 50 ⁇ M Pyro-2DG for 30 min at 37° C. in the absence (upper) and presence (lower) of 50 mM D-glucose. Left hand: fluorescence images; middle: bright field images; right hand: overlapping images.
- FIG. 4 2-Deoxyglucose conjugates targeting GLUT.
- FIG. 5 Confocal images of 9L glioma cells (ex: 630 nm; em: 640-750 mm) incubated with 50 ⁇ M Pyro-2DG for 30 min at 37° C. in the absence (upper) and presence (lower) of 50 mM D-glucose. Left column shows the Pyro-2DG fluorescent images, middle column shows the bright field images and the right column shows the overlay images.
- FIG. 6 Comparative intracellular localization of 100 ⁇ M Pyro-2DG and 10 ⁇ g/ml Rhodamine-123 (mitochondrial probe) in 9L glioma cells at 15 min post-incubation. The overlay picture clearly indicates that both Pyro-2DG and Rhodamine-123 localize in mitochondria.
- FIG. 7 Confocal images of B16 melanoma cells incubated without NIR664-2DG (first column), with 20 ⁇ M NIR664-2DG (second column), 50 ⁇ M NIR6642DG (third column), and 50 ⁇ M NIR664-2DG in competition with 25 ⁇ M D-glucose (last column), for 20 min at 37° C. Top row shows the fluorescent images and the bottom row shows the corresponding bright field images.
- FIG. 9 Pyro-2DG uptake in different organs of a Fisher 344 rat after 1 h tail vein infusion of 2 ml of 2.5 mg/kg Pyro-2DG. Liver (top left), kidney (bottom left), spleen (bottom middle) and brain (bottom right). Images of the frozen liver and of the control liver (no Pyro-2DG), respectively, appear in the top middle and right hand panels.
- FIG. 10 Real time Palomar images 10 min (top left), 1 hr (top right), 4 hr (bottom left) and 1 day (bottom middle) post-injection with NRF805-2DG. Top middle and bottom right are fluorescent images of all different organs. “T” stands for tumor, “L” stands for liver, “G” stands for gut, “K” stands for kidney, “M” stands for muscle and “S” stands for skin.
- FIG. 11 Chemical shifts of CH 2 NHBOC, CH 2 NH 2 and CH 2 NCS in 1 H NMR spectra of functionalized bacteriochlorophylls.
- FIG. 12A The HPLC chromatogram of BChlPP-2DG. RP-HPLC Column: ZARBOX-300SB_C8 — 4.6 ⁇ 250 mm; Solvent A: 0.1% TFA, B: CH 3 CN; Gradient: From 10% B to 100% B for 45 min; Flow: 1 mL/min. At this condition, the retention time of BchlPP-2DG is 38.1 min. Purity of the compound: >90%.
- FIG. 12B Absorption (top) and emission (bottom) spectra of BChlPP-2DG.
- FIG. 13A The HPLC chromatogram of BChlE6-2DG (retention time: 31.4 min, purity: 99%). HPLC method same as described in FIG. 12A .
- FIG. 13B The absorption spectrum of the 31.4 min peak (BChlE6-2DG) obtained by HPLC. The maximum emission is 758 nm (spectrum not shown).
- FIG. 14 Experimental set-up for in vivo animal tumor model imaging using the NIR phase array system.
- FIG. 15 Two-dimensional in vivo imaging of fluorescent contrast agents by the phased array system.
- the invention relates to novel chemical compounds, referred to herein as 2-deoxyglucose conjugates, or pharmaceutically acceptable salts thereof, in which a 2-deoxyglucose conjugate is represented by the formula:
- L is a linker group; and D is a diagnostic or therapeutic agent, provided that said conjugate is not [ 18 F]deoxyglucose or 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose.
- the linker group, L is a covalent bond, —NH—, -peptide-, -nucleic acid-, —O—(CH 2 ) r —O—, —NH—CH 2 —CH 2 NH—, —NH—CH(COOH)—CH 2 —NH—, —NH—CH 2 CH(COOH)—NH—, —NH—CH 2 —CH 2 —CH 2 —NH, —O—(CH 2 ) r —NH—, —S—(CH 2 ) r —NH—, S—(CH 2 ) r —C(O)—, —NH—CH 2 —C(O)—, —O—CH 2 —CH 2 —O—CH 2 —O, —NH—NH—C(O)—CH 2 —, —NH—(CH 2 ) 2 —C(O), or —NH—NH—C(O)—(CH 2 ) r —O—, —
- the linker group, L is susceptible to cleavage by cytosolic enzymes.
- the linker group, L is a peptide consisting of from about 1 to about 20 amino acids, more preferably about 1 to about 10 amino acids, and even more preferably about 1 to about 6 amino acids.
- the diagnostic or therapeutic agent, D is a photosensitive agent, an oncotherapeutic agent, a tumor diagnostic agent, an anti-AIDS agent, an antioxidant, a antirheumatic, an antiallergic, an antianemic agent, an antibiotic, an antidiabetic, an antiemetic, an antihistamine, an antiepileptic, a ⁇ -receptor blocker, a calcium antagonist, an ACE inhibitor, a bronchodilating agent, an antiasthmatic, a cholinergic, a corticoid, a dermatic, a diuretic, an enzyme inhibitor, a gout remedy, an influenza remedy, a sedative, an immunotherapeutic agent, a hepato-therapeutic agent, an antilipezic, a migraine remedy, a muscle relaxant, an anesthetic, a neuropathy preparation, an antihyperkinetic agent, a psychoactive agent, a thyreotherapeutic agent, a sex hormone, a
- the photosensitive agent of the present invention is a near infrared dye selected from the group consisting of pyropheophorbide, cyclophosphamide, cyclophosphamide derivatives, bacteriochlorin (BChl) and bacteriochlorin derivatives, Cy5.5, Cy7, the hexyl ether analog of pyropheophorbide, the hexyl ether anolog of pyropheophorbide carotenoid conjugate, benzothiazole (5F203), 4-hydroperoxy-cyclophosphamide (4HC), dicarbocyanine, and, such as NIR805, Indocyanine Green (ICG) and Cypate.
- pyropheophorbide cyclophosphamide, cyclophosphamide derivatives
- bacteriochlorin (BChl) and bacteriochlorin derivatives Cy5.5, Cy7, the hexyl ether analog of pyropheophorbide
- the invention also provides conjugates of 2-deoxyglucose, wherein the diagnostic or therapeutic agent is a photosensitive agent which is a photodynamic therapy agent, and preferably the photodynamic therapy agent is selected from the group consisting of a porphyrin, a chlorin, a bacteriochlorin, and derivatives thereof.
- the diagnostic or therapeutic agent of the present invention may also be an oncotherapeutic agent.
- the oncotherapeutic agent is preferably cyclophosphamide, 4-hydroperoxycyclophosphamide, taxol, adriamycin, or temozolomide.
- the oncotherapeutic agent is 4 hydroperoxycyclophosphamide.
- FIG. 4 Examples of 2-deoxyglucose conjugates encompassed by the present invention are shown in FIG. 4 .
- the present invention is not limited to the compounds shown in FIG. 4 , but rather these compounds are illustrative examples of conjugates encompassed herein.
- the invention also provides a method of diagnosing tumor disease in an animal comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof and detecting the presence of said conjugate in the animal.
- the invention also provides a method of treating tumor disease in an animal, comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof to treat the tumor disease of the animal.
- the tumor is a glioma.
- the invention also provides a method of treating disease in an animal using photodynamic therapy comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof, followed by exposing the animal to ultraviolet, visible or infrared radiation to treat the disease of the animal.
- the animal is exposed to near infrared radiation.
- the specific dose and duration of light again will depend upon the photosensitizer chosen.
- the fluence rate applied is preferably about 25 to about 100 mW/cm 2 , and most preferably about 50 to about 75 mW/cm 2 , while the duration of light application is about 5 to about 60 minutes, and most preferably about 20 to about 30 minutes.
- Suitable sources of light include commercially available lasers, lamps, light emitting diodes and the like.
- LED arrays Efos Canada, Inc., Mississauga, Ontario, Canada
- the lamp may be equipped with commercially available filters.
- photosensitizers for use in the present invention are useful over the range of 350 to 1300 nm, the exact range being dependent upon the particular photosensitizer.
- Preferred photosensitizers are those useful in the range of 650-1000 nm (i.e., in the near infrared (“NIR”)).
- NIR near infrared
- pyropheophorbide and bacteriochlorin are useful in the 650-900 nm n range.
- one or more quenchers can be administered before, during or after the administration of the conjugates of the present invention, but before application of light.
- Suitable quenchers include but are not limited to glutathione, trolox, flavonoids, vitamin C, vitamin E, cysteine and ergothioneine and other non-toxic quenchers, and preferably vitamin E.
- the amount of the quencher administered will depend upon the specific quencher(s) chosen and can be determined by one skilled in the art. However, when the quencher is vitamin E, the preferred dose ranges from about 10 mg/kg body weight to about 1 g/kg body weight, and most preferably about 100 mg/kg body weight.
- Administering one or more of the aforementioned quenchers is optional, and is complimentary to administering the conjugates of the present invention.
- Preferred complementary quenchers such as vitamin E, quench free radical formation generated from a Type I photoreaction via electron transfer, and may be used as a complementary protection mechanism to quenching singlet oxygen that is generated from a Type II photoreaction via energy transfer. Nevertheless, singlet oxygen is the major cytotoxic agent responsible for PDT.
- the artificial irradiation is applied from about 5 minutes to about 3 hours after administering one or more types of conjugates of the present invention.
- the artificial irradiation is applied about 10 to about 60 minutes after administering one or more kinds of conjugates of the present invention.
- the light should be applied at a sufficient wavelength, dose and duration to maximize the tumor damage, and, at the same time, to minimize the damage to the red blood cells and/or other surrounding tissue.
- the invention is directed to a method of inhibiting the growth of cancer cells, in vitro or in vivo, comprising contacting cancer cells with a conjugate of the present invention and, in the case of a conjugate containing a photodynamic therapy agent, exposing the cancer cells to an effective amount of artificial irradiation.
- the invention provides methods of inhibiting the growth of cancer cells, such as breast, lung, pancreas, bladder, ovarian, testicular, prostate, liver, retinoblastoma, Wilm's tumor, adrenocarcinoma or melanoma, and preferably, the cancer tumor is a prostate cancer tumor.
- the artificial irradiation is selected from the group consisting of artificial ultraviolet, infrared (IR), gamma-irradiation, x-ray and visible light.
- IR infrared
- NIR near-infrared
- the artificial irradiation is applied about 30 minutes to about 48 hours after administering the conjugate of the present invention (e.g., by injection), and even more preferably, about 3 to about 24 hours after administering the conjugate of the present invention.
- the light dose is 10 mW/cm 2 -100 mW/cm 2 .
- the artificial irradiation be applied for about 5 seconds to about 60 minutes, even more preferred is that the artificial irradiation be applied for about 1 minute to about 45 minutes, and most preferably, in the methods of the present invention, the irradiation is applied for about 10 to about 30 minutes.
- the present invention also provides a method for curing a subject suffering from a cancer.
- the subject may be a primate, human, ape, chimpanzee, gorilla or monkey) dog, cat, mouse, rat, rabbit, horse, goat, sheep, cow, chicken.
- the cancer may be identified as a breast, lung, pancreas, bladder, ovarian, testicular, prostate, liver, retinoblastoma, Wilm's tumor, adrenocarcinoma or melonoma.
- This method comprises administering to the subject a cancer killing amount of one or more conjugates of the present invention.
- Also provided is a method of inhibiting the proliferation of mammalian tumor cells which comprises contacting the mammalian tumor cells with a sufficient concentration of the conjugate of the invention, followed by exposure to artificial irradiation, so as to inhibit proliferation of the mammalian tumor cells.
- the subject invention further provides methods for inhibiting the growth of human tumor cells, treating a tumor in a subject, and treating a proliferative-type disease in a subject. These methods comprise administering to the subject an effective amount of the conjugate of the invention.
- the present invention encompasses pharmaceutical compositions, combinations and methods for treating human carcinomas.
- the invention includes pharmaceutical compositions for use in the treatment of human carcinomas comprising a pharmaceutically effective amount of the conjugate of the present invention and a pharmaceutically acceptable carrier.
- compositions may additionally include other drugs or antibodies treating carcinomas.
- compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspension, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions.
- dosage forms include, but are not limited to, liquid solutions or suspension, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions.
- the preferred form depends upon the mode of administration and the therapeutic application.
- compositions of the invention also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- an effective dose of the compositions of this invention may be in the range of from about 1 to about 2000 mg/kg.
- the dosage is from about 2 to about 1000 mg/kg, more preferably, 4 to about 400 mg/kg, and even more preferably, 5 to about 100 mg/kg.
- Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided doses may be administered daily or proportionally reduced depending on the specific therapeutic situation).
- the pharmaceutical carrier may be a lipid carrier.
- the lipid carrier may be a phospholipid.
- the lipid carrier may be a fatty acid.
- the lipid carrier may be a detergent.
- a detergent is any substance that alters the surface tension of a liquid, generally lowering it.
- the detergent may be a nonionic detergent.
- nonionic detergents include, but are not limited to, polysorbate 80 (also known as Tween 80 or (polyoxyethylenesorbitan monooleate), Brij, and Triton (for example Triton WR-1339 and Triton A-20).
- the detergent may be an ionic detergent.
- An example of an ionic detergent includes, but is not limited to, alkyltrimethylammonium bromide.
- the lipid carrier may be a liposome.
- a “liposome” is any membrane bound vesicle which contains any molecules of the invention or combinations thereof.
- the amount of conjugate administered in the formulation will depend upon the photosensitizer chosen. Preferably, the amount of conjugate administered is about 0.1 to about 10.0 mg/kg body weight of the subject, more preferably about 0.3 to about 6 mg/kg body weight, and even more preferably, 0.4-4.0 mg/kg body weight.
- the artificial irradiation is applied for about 10 seconds to about 60 minutes, and even more preferably, the artificial irradiation is applied for about 15 seconds to about 30 minutes.
- the present invention further provides pharmaceutical compositions which comprise the conjugates of the present invention and a pharmaceutically acceptable carrier.
- the present invention further provides a method of treating cancer in a subject cancer comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention.
- the antineoplastic agents of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle.
- a pharmaceutically acceptable carrier vehicle e.g., water, alcohol, glycol, and water.
- suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin are described, for example, in Remington's Pharmaceutical Sciences (16th ed., Osol, A., Ed., Mack, Easton Pa., 1980).
- a pharmaceutically acceptable composition suitable for effective administration such compositions will contain an effective amount of the compound, together with a suitable amount of carrier vehicle.
- a composition is said to be “pharmacologically acceptable” if its administration can be tolerated by a recipient patient.
- Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant.
- An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
- administering refers providing at least one pharmaceutical agent to a subject.
- administering includes oral administration, administration as a suppository, topical contact, intravenously, intraperitoneally, intramuscularly, subcutaneously, intranasally, enterally, parenterally, implantation of a slow release device such as a miniosmotic pump, and inhalation.
- the administration may be by continuous infusion, or by single or multiple boluses.
- the dosage will vary depending upon such factors as the recipient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage in the range of from about 1 pg/kg to about 10 mg/kg (body weight of recipient), although a lower or higher dosage can be administered.
- the dosage frequency can be repeated at intervals ranging from each day to every other month.
- the compounds of the present invention are intended to be provided to recipient subjects in an amount sufficient to induce a therapeutic effect.
- An amount is said to be sufficient to induce a therapeutic effect if the dosage, route of administration, etc. of the agent are sufficient to reduce, attenuate, or stop tumor progression.
- the compounds of the invention may be administered either alone or in combination with additional therapeutic agents.
- the administration of such agent(s) may be for either a “prophylactic” or “therapeutic” purpose.
- the agents are provided in advance of any tumor detection.
- the prophylactic administration of the compound(s) serves to prevent or attenuate any tumor formation.
- the agent(s) is provided at (or shortly after) the detection of actual tumor formation.
- compositions of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle.
- Suitable vehicles and their formulation are described, for example, in Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Pub., Easton, Pa., 1990.
- “Pharmaceutically acceptable carrier” includes any material which when combined with a therapeutic agent, retains the therapeutic agent's activity and is nonreactive with the mammal's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets, including coated tablets, and capsules. Typically, such carriers contain excipients, such as starch, milk, sugar certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods.
- Control release preparations may be achieved through the use of polymers to complex or absorb therapeutic agents.
- the controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release.
- Another possible method to control the duration of action by controlled release preparations is to incorporate the therapeutic agent(s) into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
- the therapeutic agent(s) can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin micro spheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin micro spheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
- the present invention also provides methods of making the compounds of the present invention.
- the present invention provides a method of making 2-deoxyglucose derivatives of the diagnostic and therapeutic agents of the present invention.
- the synthesis of a 2-deoxyglucose derivative of pyropheophorbide is provided.
- pyropheophorbide is first treated with N-hydroxysuccinimide in the presence of DCC.
- the pyropheophorbide succinimidyl ester so obtained is then reacted with activated D-glucosamine to yield the desired conjugate in 50% overall yield (see Scheme 1′).
- activated D-glucosamine is produced by treating D-glucosamine hydrochloride with sodium methoxide.
- an amine reactive universal linker such as isothiocyanate, is introduced into the bacteriochlorophyll (BChl) macrocycle allowing bioconjugation of these NIR dyes with biologically important molecules such as peptides, metabolites, proteins, and other affinity ligands.
- bacteriochlorin e 6 isothiocyanate BChlE6-NCS
- BChlE6-NCS can subsequently be conjugated to a 2-deoxyglucose moiety to form bacteriochlorin e 6 2-deoxyglucosamide.
- BOC-protected amino-bacteriochlorin e 6 BChlE6-BOC is formed from bacteriopheophorbide as described in more detail below.
- the bacteriopheophorbide a methyl ester is then used to produce amino-bacteriochlorin e 6 (BchlE6-NH2) and bacteriochlorin e 6 isothiocyanate (BChlE6-NCS), which is then conjugated to form BChlE6-2DG.
- UV-vis spectra were recorded on a Beckman DU-600 spectrophotometer. Fluorescence emission was measured with a Perkin-Elmer LS-50B fluorometer. 1 H NMR spectra were recorded on a Bruker ASPECT 360 M instrument. ESI-MS and HRMS spectrometric analysis were performed at the Mass Spectrometry Facility of the Department of Chemistry, University of Pennsylvania. Methyl pheophorbide a was isolated from Spirulina pacifica algae available from Cyanotech Corp., Hawaii.
- Pyropheophorbide (1) was synthesized from methyl pheophorbide according to literature procedures (Zheng, G., Li, H., Zhang, M., Chance, B., and Glickson, J. D. (2002) Low-density Lipoprotein Reconstituted by Pyropheophorbide Cholesteryl Oleate as Target Specific Photosensitizer Bioconjugate Chem. 13, 392-396). Other chemicals were purchased from Aldrich. When necessary, solvents were dried before use. For TLC, EM Science TLC plates (silica gel 60 F 254 ) were used.
- Reverse phase (RP) analytical HPLC was performed using a Zorbax RX-C8 (9.4 mm ⁇ 250 mm) column eluting at 1.0 mL/min with MeCN/phosphate buffer (0% to 99% MeCN gradient) with UV-vis detection at 414 nm.
- Pyropheophorbide succinimidyl ester (2) Pyropheophorbide (1) (208 mg 0.39 mmol) was activated with DCC (80 mg 0.39 mmol) and N-hydroxysuccinimide (92 mg 0.8 mmol) in 10 mL DMF. After stirring for 24 h, urea was filtered off, and solvents were removed. The crude product was purified by column chromatography (silica gel 60) and eluted with 5% methanol in CH 2 Cl 2 . The desired product was crystallized from CH 2 Cl 2 /hexane in 80% yield (195 mg 0.31 mmol). Mp: 200-202° C.
- Pyropheophorbide-2-deoxyglucosamide (Pyro-2DG) (3): D-Glucosamine hydrochloride (130 mg 0.6 mmol) was added to a solution of sodium methoxide (32.4 mg 0.6 mmol) in 7 mL DMSO. The mixture was stirred for 2 h, and pyropheophorbide succinimide ester (2) (190 mg 0.3 mmol) was added. The reaction mixture was stirred under argon atmosphere for 20 h. After removing solvents, the crude product was washed with dichloromethane, water and crystallized from methanol. The title compound was obtained in 102 mg yield.
- the cells were washed five times with ice-cold PBS containing 0.8% BSA, two times with PBS alone, and fixed for 20 minutes with 2% formaldehyde in PBS at room temperature. Then the chamber slides were mounted and sealed for confocal microscopic analysis.
- Rat 9L glioma was implanted on the flanks of male Fisher 344 rats (150-200 g) via subcutaneous injection of 0.1 mL, ⁇ 10 6 9L glioma cells. Within ten days, tumors grew to the desired size of 1 cm in diameter. After not feeding animals for 24 hours, the rats were anaesthetized via intraperitoneal injection of Ketamine (75 mg/kg) and Xylazine (10 mg/kg). Pyro-2DG (2 mL, concentration: 0.25 mg/mL) was injected via tail vein infusion over a period of 1 hour (dose: 2.5 mg/kg). Thirty minutes later, the rats were anesthetized again and subjected to PDT.
- PDT Protocol A “point treatment” protocol was designed for evaluating PDT response of Pyro-2DG. PDT was carried out using a KTP YAG pumped dye module (Laserscope, San Jose, Calif.) tuned to produce 670 nm light. Light delivery was through a 1 mm fiber to create a treatment spot of 0.96 mm in diameter when the fiber was held closely adjacent to the tumor. The light field was fixed in position at the center of the tumor by mounting the fiber in the center of a circular plate which was glued to the anesthetized animal. The light was delivered at a fluence rate of 75 mW/cm 2 to a total dose of 175 J/cm 2 . Laser power output was measured with a power meter (Coherent, Auburn, Calif.).
- the frozen tumor sample was milled flat and imaged every 100 ⁇ m from the top surface to the bottom of the tumor.
- the light guide (fused silica, 50 ⁇ m core diameter) stepped across the tissue surface at a fixed distance from the tissue surface (70 ⁇ m).
- the imaging resolution of the low temperature scanning fluorometer was 80 ⁇ m.
- the fluorescent signals of FP (filters: Ex: 440DF20, Em: 520DF40), PN (filters: Ex: 365HT25, Em: 455DF70), Pyro-2DG (filters: Ex: 405DF40, Em: 700ALP) were imaged for each depth of tumor.
- the scanning was performed at 128 ⁇ 128 steps that could cover 1.024 ⁇ 1.024 cm 2 .
- the fluorescence signal was automatically digitized and recorded on a PC.
- the redox ratio of PP/(FP+PN) was calculated with MATLAB.
- the pyropheophorbide was first treated with N-hydroxysuccinimide in the presence of DCC.
- the pyropheophorbide succinimidyl ester (2) so obtained was reacted with D-glucosamine that was activated by treating D-glucosamine hydrochloride with sodium methoxide to yield the desired conjugate (3) in 50% overall yield (see Scheme 1′).
- the structures of all new compounds were confirmed by HRMS and NMR spectroscopy.
- the HPLC chromatograms of the final conjugate confirmed its homogeneity.
- Pyro-2DG is only partially water-soluble due to the hydrophobic nature of the porphyrin macrocycle. Formulation with detergent (1% Tween 80) made it completely miscible with water and suitable for in vivo administration.
- a “point treatment” protocol for evaluating PDT response of Pyro-2DG was designed. Instead of irradiating the whole tumor area (1 cm in diameter), only an area ⁇ 1 mm in diameter at the center of the tumor was treated. The same laser power and light dose (75 mW/cm 2 , 175 J/cm 2 ) were used throughout the experiments.
- the 9L tumor was treated with 670 nm laser light, and a 700 nm long pass filter was incorporated into the 3D fluorescence scanner for collecting the Pyro-2DG fluorescence at 720 nm.
- This point treatment procedure is designed for two purposes: 1) to allow the adjacent untreated tumor region along with the normal tissue region to serve as internal controls; and 2) to evaluate possible bystander effects.
- the tumor specificity of Pyro-2DG is, of course, limited by uptake of glucose by various normal tissues; however, most tumors consume substantially more glucose than the surrounding normal tissues. Thus, all PDT experiments were carried out under fasting conditions. Low serum glucose levels were achieved by not feeding animals for 24 hour before the experiments. Moreover, the animals were given low concentration Pyro-2DG via tail vein infusion over a period of 1 hour to enhance the tumor uptake. Thirty minutes after injection, the animals were subjected to the PDT (75 mW/cm 2 , 175 J/cm 2 ). After PDT, animals were rapidly frozen and kept in liquid nitrogen for fluorescence imaging studies using the low temperature 3D scanning fluorometer.
- This fluorometer was designed originally to examine the redox state of in-vivo-freeze-trapped tissue (Quistorff, B., Haselgrove, J. C., and Chance, B. (1985) High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal. Biochem. 148, 389-400). It detects the intrinsic fluorescence of oxidized flavoprotein (FP, ⁇ ex : 436 nm, ⁇ em : 560 nm) and reduced pyridine nucleotide (PN, ⁇ ex : 366 nm, ⁇ em : 450 nm) stemming from mitochondria.
- FP oxidized flavoprotein
- PN reduced pyridine nucleotide
- the PN signal indicates mainly NADH, whereas the PP signal originates from the flavins of dehydrolipoamide dehydrogenase component of pyruvate dehydrogenase and ⁇ -ketoglutarate dehydrogenase.
- the flavoproteins are coupled to the mitochondrial NAD/NADH redox system by pyruvate dehydrogenase and ⁇ -ketoglutarate dehydrogenase reactions, and 2) only the reduced form of the PN system and the oxidized species of PP couple are strongly fluorescent, the ratio of FP/(FP+PN) calculated from FP and PN signals accurately represents the redox state of the mitochondrial NAD/NADH redox couple (Chance, B., Schoener, B., Oshino, R., Itshak, P., and Nadase, Y. (1979) Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-Trapped Samples. J. Biol. Chem.
- the redox ratio can be used to evaluate the PDT damage to the tumor mitochondria.
- this fluorometer is also useful in detecting any exogenous fluorophore (e.g. Pyro-2DG) that is present in the specimen.
- FIG. 1 shows the redox ratio images (the first column), their corresponding histograms (the second column) and the Pyro-2DG fluorescence images (the third column) of 9L glioma and surrounding muscle tissue.
- the x and y axes of images represents the number of pixels scanned, whereas x and y axes of the histograms represents the relative redox ratio value and its corresponding pixel number, respectively.
- Pyro-2DG is selectively accumulated inside the tumor margin (top row images) compared to surrounding normal tissue such as muscle (middle row images), and there is no background fluorescence observed from the control experiment in which tumor is imaged in the absence of Pyro-2DG (bottom row images).
- the ratio of FP/(FP+PN) represents the redox state of the mitochondrial NAD/NADH redox couple
- the significant enhancement of this ratio clearly reflects the extensive mitochondrial damage (oxidation) experienced by the irradiated region of the tumor, but not the adjacent unirradiated region.
- the complete disappearance of the Pyro-2DG fluorescence signal was observed in the same region (there is a dark “hole” at the center of the tumor, see the last image of the top row), indicating selective photobleaching of the photosensitizer.
- a new photosensitizer targeted at the GLUT pathway to serve as both a targeted PDT agent and a NIR imaging agent has been designed and synthesized.
- Pyro-2DG selectively accumulated in the tumor compared to the surrounding normal tissue as observed by measuring its NIR fluorescence at 720 nm using a low-temperature 3D fluorescence scanner.
- this agent efficiently causes selective mitochondrial damage to the region of a tumor that was photoirradiated after administration of this agent, but does not affect tissues photoirradiated in the absence of the agent or tissues treated with the agent that are not photoirradiated.
- the confocal microscopy data are consistent with the hypothesis that Pyro-2-DG has been delivered and trapped in tumor cells via the GLUT/hexokinase pathway, and therefore, Pyro-2DG is useful both as a tumor-selective NIR fluorescence imaging probe and as a PDT agent.
- 9L glioma cells obtained from Department of Radiation Oncology at University of Pennsylvania, were cultured in Modified Eagle's Medium (MEM) supplemented with 15% newborn calf serum (NCS), 100 U/ml penicillin-streptomycin.
- Murine melanoma B16 cells obtained from Dr. Theo van Berkel's laboratory at the University of Leiden, Netherlands, were cultured in Dulbeco's modified Eagle's medium (DI) supplemented with 10% fetal bovine serum SOBS) and 100 U/n-d penicillin-streptomycin Cells were grown at 37° C. in an atmosphere of 5% CO 2 in a humidified incubator.
- DI Dulbeco's modified Eagle's medium
- SOBS fetal bovine serum
- NIRF-2DGs with or without D-Glucose and Rbodarninc-123 were incubated with 9L glioma cells/B16 melanoma cells at 37° C. for 30 min after 3 washes with Dulbecco's Phosphate Buffered Saline (D-PBS). After incubation, the cells were washed five times with ice-cold PBS and Fixed for 20 minutes with 2% formaldehyde in PBS at room temperature. Then the chamber slides were mounted and sealed for confocal microscopic analysis. Confocal aticroscopic images were obtained with TCS SPII laser scanning confocal microscope (LSCM) (Heidelber, Germany).
- LSCM laser scanning confocal microscope
- 9L glioma bearing rat model was obtained by implanting 2 ⁇ 106 Cells in the flank of male Fisher 344 rats (150-200 g) via subcutaneous injection. Animals were studied when tumor size reached 2 cm ⁇ 1.8 cm.
- KB tumor (squamous cell carcinoma) bearing nu/nu mouse model was also used. The average tumor size was 0.8 cm ⁇ 0.8 cm.
- the 9L glioma-bearing rat was anaesthetized intraperitoneally by injecting Ketamine (75 mg/kg) and Xylazine (10 ing/kg) and was given Pyro-2DG (1 mL, concentration: 0.5 mg/ml) via tail vein injection within 2 min. After 2 hirs, the rat was immersed in pre-cooled isopentane ( ⁇ 150° C.) and transferred to liquid nitrogen ( ⁇ 196° C.) 5 minutes later. Tumors and the surrounding muscle tissues were then surgically excised, embedded in a mixture buffer (ethaiiol-glycerol-water, freeze point: ⁇ 30° C.), and mounted for fluorescent Cryo-imaging.
- Ketamine 75 mg/kg
- Xylazine 10 ing/kg
- Pyro-2DG 1 mL, concentration: 0.5 mg/ml
- the rat was immersed in pre-cooled isopentane ( ⁇ 150° C.) and transferred to liquid nitrogen (
- the frozen tumor sample was ground flat and then further ground to obtain images every 100 ⁇ m from the top surface to the bottom of the tumor.
- a bifurcated optical fiber bundle (7 quartz fibers, 70 pi core diameter for each, 0.34 numerical aperture, 1 fiber for emission in center, 6 fibers for excitation around the emission fiber) stepped across the tissue surface at a fixed distance.
- the excitation filter and the emission filter for detecting the fluorescent signals of each substance were designed based on the absorption and emission spectra of each fluorophores (See FIG. 1 ).
- the fluorescent signals of oxidized flavoprotein Fp, filters: Ex: 44ODF20, Em: 52ODF40
- reduced pyridine nucleotide PN, filters; Ex: 365HT125, Em: 455DF70
- the redox ratio of PN/(Fp+PN) and Fp/(FP+PN) calculated with MATLAB represented the reduced state and oxidized state of the mitochondria, respectively.
- the scanning was performed at 128 ⁇ 128 steps that covered 1,024 ⁇ 1.024 cm 2 area (80 ⁇ m in-plane resolution).
- NIR805-2DG probe 100 ⁇ L of 1 ⁇ M was administered intravenously to the nu/nu mice with KB tumors.
- a series of real time PalomarTM images were taken at different time points.
- the Palomar Imager developed by the Spectros Corp., CA, is a flexible system designed for imaging the distribution and localization of targeted fluorescent agents in small animals and humans in room light surgical operating room conditions.
- NIRF-2DG conjugates by replacing the [ 18 F] atom at the 2-position of the FDG with fluorophores based on either tetrapyrrole dyes or cyanine dyes.
- imaging agents are pyropheophorbide 2-deoxyglucosamide Pyro-2DG), two bacteriochlorin 2-deoxyglucosamides (BChlPP-2DG and BChlE6-2DG), dicarbocyanine 2-deoxyglucosamide (NIR664-2DG) and two tricarbocyanine 2-deoxyglucosamides, NIR805-2DG and Cypate-2DG.
- FIG. 8 illustrated that Pyro-2DG accumulated preferentially in the 9L glioma tumors of fasted rats relative to adjacent skeletal muscle at a ratio of 10:1.
- the fluorescent signal glows everywhere, with a signal forming slightly then strongly over the liver with no localized signal con-Ling from the tumor (T). There is no signal at the tumor, in part due to the scaling of the image (since too much signal everywhere, so scale is raised to see only the liver outline). After 1 hr, the signal is primarily over the liver. By 4 hours, the dorsal tumor glows brightly, and there is less dye signal from the liver. At 1 day, there is a large amount of signal in the gut (G) in the abdomen, but tumor signal still was observed. This study clearly demonstrated that the utility of NIRF-2DG as NIR fluorescent imaging agents for the detection of tumor in vivo.
- UV-vis spectra were recorded on a Beckman DU-600 or a Perkin-Elmer Lambda spectrophotometer. Fluorescence emission was measured with a Perkin-Elmer LS-50B fluorometer. 1 H NMR spectra were recorded on a Bruker ASPECT 360 MHz instrument. ESI-MS and HRMS spectrometry analysis were performed at the Mass Spectrometry Facility of the Department of Chemistry, University of Pennsylvania. Methyl pheophorbide a was obtained from Spirulina pacifica algae available from Cyanotech Corp., Hawaii.
- Purpurin-18 methyl ester (1) was synthesized from methyl pheophorbide according to a literature procedure. (Zheng, G.; Li, H.; Zhang, M.; Lund-Katz, S.; Chance, B.; Glickson, J. D., Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjugate Chemistry 2002, 13, (3), 392-396.) Bacteriochlorophyll a (BChl) was extracted from R Sphaeroides biomass purchased from Frontier Science, Utah.
- Bacteriopurpurin-18 methyl ester (6) and bacteriopheophorbide a methyl ester (11) were synthesized from BChl according to previously described procedures. (Kozyrev, A. N.; Zheng, G.; Zhu, C. F.; Dougherty, T. J.; Smith, K. M.; Pandey, R. K., Syntheses of stable bacteriochlorophyll-a derivatives as potential photosensitizers for photodynamic therapy.
- Bacteriopurpurin-18-N-3′-(BOC-amino)propylimide, BChlPP-BOC (7) Bacteriopurpurin-18 methyl ester (6) (100 mg, 0.186 mmol) and tert-Butyl N-(3-aminopropyl)-carbamate (250 mg, 1.44 mmol) were dissolved in benzene (7 mL). The solution was refluxed at 78° C. under argon atmosphere for 48 hrs. After removing solvent, the residue so obtained was purified by silica gel column chromatography with 5% MeOH in CH 2 Cl 2 to afford the title compound in 18% yield (24 mg).
- Bacteriopurpurin-18-N-3′-(isothiocyanate)propylimide, BChlPP-NCS (9) Amino derivatives of bacteriopurinimide (18 mg, 0.027 mmol) and 1,1′-thiocarbonyldiimidazole (5.3 mg, 0.0298 mmol) were dissolved in CH 2 Cl 2 (2 mL). The solution was stirred at room temperature under argon atmosphere for 20 hrs. After removing solvent, the residue was purified by silica gel plate chromatography with 2% MeOH in CH 2 Cl 2 to obtain the desired product in 75% yield (14 mg).
- BChlE6-NH 2 was then used directly for the next reaction step without further purification.
- BChl-NH 2 300 mg, 0.43 mmol
- 1,1′-thiocarbonyldiimidazole 71.3 mg
- the reaction mixture was subsequently refluxed at 40° C. under argon atmosphere for 3 h, and the solvent was removed.
- the residue was purified by silica gel chromatography with 2% MeOH—CH 2 Cl, and 95 mg of BChlE6-NCS was collected (yield 75%).
- NIR optical imaging system To image and localize subsurface fluorochrome labeled tumors, an NIR imaging system utilizing diffusion photons (Patterson, M. S.; Chance, B.; Wilson, B. C., Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. Applied Optics 1989, 28, 2331-2336.
- the in vivo fluorescence optical imaging system consists of a pair of laser diodes operating at 780 nm. The light intensities are modulated by 50 MHz sinusoidal radio frequency waves, but with a 180° phase difference between them. Detection sensitivity and localization accuracy are enhanced through phase cancellation techniques. (Chance, B.; Kang, K.; He, L.; Weng, J.; Sevick-Muraca, E. M., Highly sensitive object location in tissue models with linear in-phase and anti-phase multi-element optical arrays in one and two dimensions. Proceedings of the National Academy of Sciences USA 1993, 90, 3423-3427.
- the excitation photons are delivered to the imaging chamber filled with highly scattering medium (Intralipid® and ink) through fiber optics.
- highly scattering medium Intralipid® and ink
- the tumor-bearing animal injected with BChlPP-2DG is immersed inside the imaging chamber, and the tumor is placed within 1.5 cm from the outside surface.
- a 3-mm-in-diameter fiber bundle collects the fluorescence signal from the fluorophore taken by in the tumor.
- An interference filter at 830 nm is used to select the emitted fluorescent photons.
- the fluorescence signal is then detected by the photomultiplier tube (PMT) and demodulated by the 50 MD receiver to obtain the amplitude and phase information.
- the imaging probe consists of two source fibers with a separation of 2 cm and a detection fiber bundle with equal distance (4 cm) from each source.
- the source and detector fibers can be scanned in tandem under the control of a stepper motor. After finishing one axial scan, the probe can be rotated to another angle to perform another axial scan. Multiple radial scans in different directions can be acquired for object localization. (Chen, Y.; Mu, C. P.; Intes, X.; Blessington, D.; Chance, B., Near-infrared phase cancellation instrument for fast and accurate localization of fluorescent heterogeneity.
- the optical imaging probe is placed on the surface of the imaging chamber and scanned through a 5-cm-in-diameter area for subsurface localization of fluorescence enhanced tumor.
- Two-dimensional localization of the subsurface fluorochrome is obtained by fitting the experimental data to the analytical solutions and searching for the minimum of the probability function ⁇ 2 .
- the reactive functional groups that are added should not only be stable enough for prolonged storage ability but should also exhibit high labeling efficiencies with minimal side reactions; ultimately, they must produce a stable covalent bond.
- Isothiocyanate has been widely used for coupling with primary and secondary amines of biologically important molecules; (Flanagan, J. H.; Khan, S. H.; Menchen, S.; Soper, S. A.; Hammer, R. P., Functionalized tricarbocyanine dyes as near-infrared fluorescent probes for biomolecules. Bioconjugate Chemistry 1997, 8, (5), 751-756.) thus, it became the labeling functionality of choice.
- Pandey et al. have shown that unstable bacteriochlorophyll a analogs containing a five-member isocyclic ring can be converted to the related bacteriochlorin bearing either a fused six-member anhydride or imide ring systems; these derivatives are referred to as bacteriopurpurin-18 (BChlPP) and bacteriopurpurinimide analogs, respectively.
- BChlPP bacteriopurpurin-18
- bacteriopurpurinimide analogs respectively.
- bacteriopurpurin-18-N-3′-(amino)propylimide BChlPP-NH 2 , 8) was synthesized from bacteriopurpurin-18-N-3′-(BOC-amino)propylimide (BChlPP-BOC, 7) and converted successfully to bacteriopurpurin-18-N-3′-(isothiocyanate)propylimide (BChlPP-NCS, 9) as shown in Scheme 1.
- the overall yield of BChlPP-NCS from BChlPP dropped from 50% to 10% with BChlPP-BOC formation as the yield-limiting step.
- BChlE6-2DG was confirmed by 1 H, 13 C NMR and high resolution mass spectrometry.
- the purity of BChlE6-2DG was 99% by RP-HPLC.
- FIG. 13 shows the HPLC chromatogram and the absorption spectra of the final conjugate.
- the amount of injected contrast agents is usually 200 ⁇ L at a concentration of 1 mg/mL.
- the scattering media has similar optical properties as human breast tissue for studies of breast cancer models, and is maintained at physiological temperature ( ⁇ 37° C.).
- the tumor cells are hyper-metabolic compared with normal cells; consequently, they take up more glucose contrast agents into the tumor cells than nearby normal tissues.
- the mouse is kept alive throughout the experiment.
- the optical imaging probe is placed on the surface of the imaging chamber and scanned through a 5-cm-in-diameter area for subsurface localization of fluorescence enhanced tumor.
- FIG. 15 a is the image obtained from BChl-2DG treated animals. The tumor region is enhanced.
- FIG. 15 b shows the image of the mouse tumor following tail-vein injection of ICG.
- ICG intracranial pressure
- FIG. 15 c illustrates a negative control animal without the injection of the contrast agents; under these conditions the fluorescence phased array system does not detect the signals from the tumor.
- BChlPP-2DG was further tested in vivo in animal tumors using a phase array NIR optical imaging system and showed promise as a the tumor-targeting agent for the detection and treatment of subsurface cancers.
Abstract
The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neoplastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker is attached to a therapeutic or diagnostic agent. The inventions also relates to methods of treating tumor disease and methods of making the novel compounds of the present invention. The agents of the present invention are superior to previous agents as they are targeted via GLUT transporters.
Description
- The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant Nos. R21 CA95330 (GZ), N01-CO37119 (GZ), NO1-CM97065 (BC), P20 CA86255 (JDG), R24 CA83105 (JDG) and RO1 CA85831 (TMB) awarded by NIH.
- 1. Field of the Invention
- The invention is in the field of antineoplastic agents and cancer diagnostic agents. More particularly, the invention pertains to novel 2-deoxyglucose conjugates, their use and methods of making such compounds.
- 2. Related Art
- One of the biochemical “hallmarks” of malignancy is enhanced tumor glycolysis, which is primarily due to the overexpression of glucose transporters (GLUTs) and the increased activity of mitochondria-bound hexokinase in tumors (Medina, R. A. and Owen, G. I. (2002) Glucose transporters: expression, regulation and cancer. Biol. Res. 35, 9-26). Utilizing these cancer signatures, [18F] 2-fluoro-2-deoxyglucose (18FDG) based positron emission tomography (PET) has become a widely used molecular imaging modality in the detection of a wide range of human cancers (Czernin, J. and Phelps, M. E. (2002) Positron emission tomography scanning: current and future applications. Ann. Rev. Med. 53, 89-112).
- 18FDG is an analog of glucose that enters cells via glucose transporters (GLUT) and is phosphorylated to 18FDG-6-phosphate by hexokinase, the first enzyme in the glycolytic pathway. This enzyme converts glucose, 2-deoxyglucose or 18FDG from a neutral, membrane-permeable form to an anionic, membrane-impermeable form. Reversal of this reaction requires glucose-6-phosphatase, which is generally not present at high enough concentration in most cells to mediate this reaction. Further metabolism of 18FDG-6-phosphate by phosphoglucose isomerase, the next enzyme in the glycolytic pathway, or by enzymes in the glycogen or pentose shunt pathways does not occur (Pauwels, E. K, Ribeiro, M. J., Stoot, J. H., McCready, V. R., Bourguignon, M., and Maziere, B. (1998) FDG accumulation and tumor biology. Nuclear Med. Biol. 25, 317-322). Therefore, 18FDG-6-phosphate is trapped in the cell. The high affinity of 18FDG for tumors derives from the high levels of aerobic glycolysis (Vaupel, P., Kallinowski, F., and Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465) and overexpression of GLUTs exhibited by most, but not all (Weinhouse, S. (1976) The Warburg hypothesis fifty years later. Z. fur Krebsforsch. Klin. Onkol. 87, 115-126), tumors.
- Speizer in 1985 (Speizer, L., Haugland, R., and Kutchai, H. (1985) Asymmetric transport of a fluorescent glucose analogue by human erythrocytes. Biochim. Biophys. Acta 815, 75-84), exploited the glucose transport pathway to deliver a fluorescent analog of glucose, 6-deoxy-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-aminoglucose, into human erythrocytes. This analog is a derivative of 6-deoxyglucose containing a fluorophore on the 6-position. A fluorescent derivative of 2-deoxyglucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG) (Ex: 475 nm; Em: 550 nm), was introduced by Yoshioka et al. in 1996 (Yoshioka, K., Takahashi, X, Homma, T., Saito, M., Oh, K. B., Nemoto, Y., and Matsuoka, R. (1996) A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim Biophys. Acta 1289, 5-9), who demonstrated that localization of this agent in the yeast Candida albicans was inhibited by D-glucose, but not L-glucose. Similar D-glucose (but not L-glucose) inhibited uptake of 2-NBDG has been demonstrated in E. coli (Yoshioka, K., Takahashi, H., Homma, T., Saito, M., Oh, K. B., Nemoto, Y., and Matsuoka, H. (1996) A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim. Biophys. Acta 1289, 5-9; Yoshioka, K., Saito, M., Oh, K. B., Nemoto, Y., Matsuoka, H., Natsume, M., and Abe, H. (1996) Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells. Biosci. Biotech. Biochem. 60, 1899-1901; and Natarajan, A. and Srienc, F. (2000) Glucose uptake rates of single E. coli cells grown in glucose-limited chemostat cultures. J. Microbiol. Methods, 42, 87-96), yeast (Natarajan, A. and Srienc, P. (2000) Glucose uptake rates of single B. coli cells grown in glucose-limited chemostat cultures. J. Microbiol. Methods, 42; 87-96), vascular smooth muscle cells (Oh, K. B. and Matsuoka, H. (2002) Rapid viability assessment of yeast cells using vital staining with 2-NBDG, a fluorescent derivative of glucose. Intl. J. Food Microbiol. 76, 47-53), and pancreatic β-cells transfected to overexpress Glut2 glucose transporters (Lloyd, P. G., Hardin, C. D., and Sturek, M. (1999) Examining glucose transport in single vascular smooth muscle cells with a fluorescent glucose analog. Physiol. Res. 48, 401-410).
- Utilization of the glucose transport system was further supported by competitive inhibition of 2-NBDG uptake by the glucose analogs 3-O-methyl glucose and D-glucosamine (Yoshioka, K., Saito, M., Oh, K. B., Nemoto, Y., Matsuoka, H., Natsume, M., and Abe, H. (1996) Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells. Biosci. Biotech Biochem. 60, 1899-1901). Internalization of 2-NBDG in isolated rabbit enterocytes was demonstrated by confocal microscopy (Roman, Y., Alfonso, A., Louzao, M. C., Vieytes, M. R., and Botana, L. M. (2001) Confocal microscopy study of the different patterns of 2-NBDG uptake in rabbit enterocytes in the apical and basal zone. Pflugers Arch.—Eur. J. Physiol. 443, 234-239). Conversion of 2-NBDG to 2-NBDG-6-phosphate in E. coli cells was confirmed by mass spectrometry and by demonstration that glucose-6-phosphatase regenerated 2-NBDG (Yoshioka, K., Saito, M., Oh, K. B., Nemoto, Y., Matsuoka, H., Natsume, M., and Abe, H. (1996) Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells. Biosci. Biotech. Biochem. 60, 1899-1901). Localization of 2-NBDG in rat 9L glioma has recently been reported by Baidoo et al. (Baidoo, K. E., Mathews, W., and Wagner, H. N. (2000) Fluorescent imaging of deoxyglucose. 8th Intl. Conf: Peace through Mind/Brain Science Hamamatsu, Japan, February 2-4). These authors found that animals injected with 2-NBDG under fasting conditions (low serum glucose level) accumulated this probe in tumors, and uptake of 2-NBDG could be blocked under non-fasting conditions (high serum glucose level).
- Additionally, U.S. Pat. No. 6,489,302 relates to a conjugate, comprising a saccharide and one or more therapeutic or diagnostic agents for treatment and diagnosis of cancer and viral disease which uses the GLUT pathway.
- Near-infrared (NIR) dyes are presently attracting considerable interest as fluorescence probes for detection of cancer ((a) Lin, Y., Weissleder, R., and Tung, C. H. (2002) Novel near-infrared cyanine fluorochromes: synthesis, properties, and bioconjugation. Bioconjugate Chem. 13, 605-610. (b) Achilefu, S., Jimenez, H. N., Dorshow, R. B., Bugaj, J. B., Webb, E. G., Wilhelm, R. R., Rajagopalan, R., Johler, J., Erion, J. L. (2002) Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J. Med. Chem. 45, 2003-2015. (c) Mujumdar, S. R., Mujumdar, R. B., Grant, C. M., and Waggoner, A. S. (1996) Cyanine-labeling reagents: sulfobenzindocyanine succinimidyl esters. Bioconjugate Chem. 7, 356-362) and as photosensitizers for cancer treatment by photodynamic therapy (PDT) (Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., and Peng, Q. (1998) Photodynamic therapy. J. Natl. Cancer Inst. 90, 889-905). Since tissue is relatively transparent to NIR light, NIR fluorescence imaging (NIRF) and PDT are capable of detecting and treating, respectively, even subsurface tumors. Owing to the need to increase photosensitizers' water solubility and to increase their affinity for tumor tissues, a great deal of effort has been devoted by many research groups to develop photosensitizers covalently linked with various carbohydrate moieties ((a) Sternberg, E. D., Dolphin, D. and Bruckner, C. (1998) Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron 54, 4151-4202. (b) Licha, K. (2002) Contrast agents for optical imaging. Top. Cur. Chem. 222, 1-29). However, none of them was intended to take advantage of the intracellular trapping mechanism for 2DG in tumor cells as it does for FDG.
- A key limitation of cancer drugs is their lack of specificity for tumor cells. There is therefore a need to develop tumor-specific agents that are targeted at GLUT transporters, which constitute the main pathway that tumor cells utilize for import of substrates for energy production. Since glucose is the principal substrate for energy production utilized by most if not all tumors the agents which target this critical pathway should exhibit a substantially enhanced level of tumor specificity.
- Stable bacteriochlorophyll (BChl) analogs derived from R. Sphaeroides are excellent NIR dyes for NIRF and PDT because of their favorable photophysical properties (1O2 yield: 45%) and long activation and fluorescence emission wavelengths (750-850 nm). (Pandey, R. K.; Zheng, G., Porphyrins as Photosensitizers in Photodynamic Therapy. In The Porphyrin Handbook, ed.; Kadish, K. M.; Smith, K. M.; Guilard, R., Eds. Academic Press: Boston, 2000; Vol. 6, pp 157-230.) Since native BChl is very unstable and undergoes rapid oxidation to the chlorin state (660 nm), preparation of a stable BChl analog is a synthetic challenge. In recent years, many approaches to remove the major points of fragility in the BChl a molecule have been tried by various investigators. These include replacing the central metal, magnesium, with other metal ions (e.g., palladium) to form stable complexes, Fiedor, J.; Fiedor, L.; Kammhuber, N.; Scherz, A.; Scheer, H., Photodynamnics of the bacteriochlorophyll-carotenoid system. 2. Influence of central metal, solvent and beta-carotene on photobleaching of bacteriochlorophyll derivatives. Photochemistry & Photobiology. 2002 August; 76(2):145-52; Schreiber, S.; Gross, S.; Brandis, A.; Harmelin, A.; Rosenbach-Belkin, V.; Scherz, A.; Salomon, Y., Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery. International Journal of Cancer. 2002 May 10; 99(2):279-85.) modifying the isocyclic ring, and replacing the phytyl group at the propionyl residue either through transesterification or by conversion to the corresponding amide derivatives. (Rosenbach-Belkin, V.; Chen, L.; Fiedor, L.; Tregub, I.; Paviotsky, F.; Brumfeld, V.; Salomon, Y.; Scherz, A., Serine conjugates of chlorophyll and bacteriochlorophyll: photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Photochemistry & Photobiology. 1996 July; 64(1):174-81.) In particular, Pandey, et al. have shown that naturally occurring unstable BChl a (extracted from Rb. Sphaeroides) can be converted to the stable bacteriochlorins, bacteriopurpurin-18 and bacteriopurpuriniride. (Kozyrev, A. N.; Zheng, G.; Zhu, C. F.; Dougherty, T. J.; Smith, K. M.; Pandey, R. K., Syntheses of stable bacteriochlorophyll-a derivatives as potential photosensitizers for photodynamic therapy. Tetrahedron Letters 1996, 37, (36), 6431-6434; Chen, Y.; Graham, A.; Potter, W.; Morgan, J.; Vaughan, L.; Bellnier, D. A.; Henderson, B. W.; Oseroff, A.; Dougherty, T. J.; Pandey, R. K., Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy. Journal of Medicinal Chemistry. 2002 Jan. 17; 45 (2):255-8.) In this approach, converting the fused isocyclic ring to a cyclic imide moiety enhanced the stability and solubility of the BChl analogs. Attachment of a variable alkyl substituent to the imide moiety allowed the lipophilicity of the molecule to be fine-tuned. Some of these agents are highly potent against radiation-induced fibrosarcoma (RIF-1) in mice. In another elegant demonstration, Fiedor et al. found that inserting palladium into the BChl ring significantly improves its stability toward reactive oxygen species. (Fiedor, J.; Fiedor, L.; Kammhuber, N.; Scherz, A.; Scheer, H., Photodynamics of the bacteriochlorophyll-carotenoid system. 2. Influence of central metal, solvent and beta-carotene on photobleaching of bacteriochlorophyll derivatives. Photochemistry & Photobiology. 2002 August; 76(2):145-52.) One such compound, Tookad®, is now under clinical evaluation for treating prostate cancer. To achieve higher levels of tumor selectivity, target-specific BChls derived from stable BChl suitable by bioconjugation are desired. For this purpose, a universal linker introduced into a stable BChl molecule that will facilitate binding of biomolecules such as peptides, proteins, and other affinity ligands is desirable. Accordingly, the present invention provides synthesis of novel functionalized BChl dyes containing an isothiocyanate moiety, their bioconjugation to cancer targeting agents, and the in vivo optical imaging of animal tumors with these new bioconjugates.
- The present invention relates to novel chemical compounds, referred to herein as 2-deoxyglucose conjugates or pharmaceutically acceptable salts thereof, in which a 2-deoxyglucose conjugate is represented by the formula:
- wherein L is a linker group; and D is a diagnostic or therapeutic agent, provided that said conjugate is not [18F]deoxyglucose or 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose.
- In addition, the present invention provides methods of making the novel chemical compounds of the present invention.
- The present invention also relates to pharmaceutical and veterinary compositions comprising one or more of the 2-deoxyglucose conjugates of the present invention, and one or more pharmaceutically acceptable diluents, carriers or excipients.
- The invention further relates to a method of treating tumor disease in an animal, comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof to treat the tumor disease of the animal.
-
FIG. 1 . Fluorescence images of drug control (top row: tumor+Pyro-2DG), normal tissue control (middle row: normal tissue of the same animal) and tumor control (bottom row, tumor alone) in 9L glioma bearing animals. Note: The tumor and normal muscle margin are outlined with a black circle in the redox ratio images (the first column), the redox ratio histograms corresponding to the marked region (black circle) are also presented here (the second column). -
FIG. 2 . Selective tumor destruction by PDT corresponds to a marked change in the intrinsic fluorescence of tumors (decreased NADH, increased FP) and the selective photobleaching of Pyro-2DG. (Top row: PDT of tumor with Pyro-2DG; bottom row: light control, PDT of tumor without Pyro-2DG). Note: The irradiated region is marked as a white cross, and the tumor margin is outlined with a black circle in both experiments. -
FIG. 3 . Confocal microscopy images of 9L glioma cells incubated with 50 μM Pyro-2DG for 30 min at 37° C. in the absence (upper) and presence (lower) of 50 mM D-glucose. Left hand: fluorescence images; middle: bright field images; right hand: overlapping images. -
FIG. 4 . 2-Deoxyglucose conjugates targeting GLUT. -
FIG. 5 . Confocal images of 9L glioma cells (ex: 630 nm; em: 640-750 mm) incubated with 50 μM Pyro-2DG for 30 min at 37° C. in the absence (upper) and presence (lower) of 50 mM D-glucose. Left column shows the Pyro-2DG fluorescent images, middle column shows the bright field images and the right column shows the overlay images. -
FIG. 6 . Comparative intracellular localization of 100 μM Pyro-2DG and 10 μg/ml Rhodamine-123 (mitochondrial probe) in 9L glioma cells at 15 min post-incubation. The overlay picture clearly indicates that both Pyro-2DG and Rhodamine-123 localize in mitochondria. -
FIG. 7 . Confocal images of B16 melanoma cells incubated without NIR664-2DG (first column), with 20 μM NIR664-2DG (second column), 50 μM NIR6642DG (third column), and 50 μM NIR664-2DG in competition with 25 μM D-glucose (last column), for 20 min at 37° C. Top row shows the fluorescent images and the bottom row shows the corresponding bright field images. -
FIG. 8 . Tumor versus normal muscle ratio of Pyro-2DG in 9L glioma bearing rats was determined as IO: I calculated from the fluorescence intensity and concentration correlation [x=(y−32.3 75)/10.7292] determined by phantom. -
FIG. 9 . Pyro-2DG uptake in different organs of a Fisher 344 rat after 1 h tail vein infusion of 2 ml of 2.5 mg/kg Pyro-2DG. Liver (top left), kidney (bottom left), spleen (bottom middle) and brain (bottom right). Images of the frozen liver and of the control liver (no Pyro-2DG), respectively, appear in the top middle and right hand panels. -
FIG. 10 . Realtime Palomar images 10 min (top left), 1 hr (top right), 4 hr (bottom left) and 1 day (bottom middle) post-injection with NRF805-2DG. Top middle and bottom right are fluorescent images of all different organs. “T” stands for tumor, “L” stands for liver, “G” stands for gut, “K” stands for kidney, “M” stands for muscle and “S” stands for skin. -
FIG. 11 . Chemical shifts of CH2NHBOC, CH2NH2 and CH2NCS in 1H NMR spectra of functionalized bacteriochlorophylls. -
FIG. 12A . The HPLC chromatogram of BChlPP-2DG. RP-HPLC Column: ZARBOX-300SB_C8—4.6×250 mm; Solvent A: 0.1% TFA, B: CH3CN; Gradient: From 10% B to 100% B for 45 min; Flow: 1 mL/min. At this condition, the retention time of BchlPP-2DG is 38.1 min. Purity of the compound: >90%. -
FIG. 12B . Absorption (top) and emission (bottom) spectra of BChlPP-2DG. -
FIG. 13A . The HPLC chromatogram of BChlE6-2DG (retention time: 31.4 min, purity: 99%). HPLC method same as described inFIG. 12A . -
FIG. 13B . The absorption spectrum of the 31.4 min peak (BChlE6-2DG) obtained by HPLC. The maximum emission is 758 nm (spectrum not shown). -
FIG. 14 . Experimental set-up for in vivo animal tumor model imaging using the NIR phase array system. -
FIG. 15 . Two-dimensional in vivo imaging of fluorescent contrast agents by the phased array system. (a) The localization of the 8 mm×8 mm submerged mouse tumor with tail vein injection of 200μL 1 mg/mL BChlPP-2DG. (b) The localization of the 8 mm×4 mm submerged mouse tumor with tail vein injection of 200μL 1 mg/mL ICG. (c) The localization of the 8 mm×6 mm submerged mouse tumor without injection of any contrast agent. In all cases, the tumors are 1.5 cm deep inside the media and the red dashed circle indicates the location and size of the tumor. - The invention relates to novel chemical compounds, referred to herein as 2-deoxyglucose conjugates, or pharmaceutically acceptable salts thereof, in which a 2-deoxyglucose conjugate is represented by the formula:
- wherein L is a linker group; and D is a diagnostic or therapeutic agent, provided that said conjugate is not [18F]deoxyglucose or 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose.
- In a preferred embodiment, the linker group, L, is a covalent bond, —NH—, -peptide-, -nucleic acid-, —O—(CH2)r—O—, —NH—CH2—CH2NH—, —NH—CH(COOH)—CH2—NH—, —NH—CH2CH(COOH)—NH—, —NH—CH2—CH2—CH2—NH, —O—(CH2)r—NH—, —S—(CH2)r—NH—, S—(CH2)r—C(O)—, —NH—CH2—C(O)—, —O—CH2—CH2—O—CH2—O, —NH—NH—C(O)—CH2—, —NH—(CH2)2—C(O), or —NH—NH—C(O)—(CH2)r—C(O)NH—N═, wherein r, in each instance, is from 2-5. Preferably, the linker group, L, is susceptible to cleavage by cytosolic enzymes. Preferably, the linker group, L, is a peptide consisting of from about 1 to about 20 amino acids, more preferably about 1 to about 10 amino acids, and even more preferably about 1 to about 6 amino acids.
- In further embodiments, the diagnostic or therapeutic agent, D, is a photosensitive agent, an oncotherapeutic agent, a tumor diagnostic agent, an anti-AIDS agent, an antioxidant, a antirheumatic, an antiallergic, an antianemic agent, an antibiotic, an antidiabetic, an antiemetic, an antihistamine, an antiepileptic, a β-receptor blocker, a calcium antagonist, an ACE inhibitor, a bronchodilating agent, an antiasthmatic, a cholinergic, a corticoid, a dermatic, a diuretic, an enzyme inhibitor, a gout remedy, an influenza remedy, a sedative, an immunotherapeutic agent, a hepato-therapeutic agent, an antilipezic, a migraine remedy, a muscle relaxant, an anesthetic, a neuropathy preparation, an antihyperkinetic agent, a psychoactive agent, a thyreotherapeutic agent, a sex hormone, a sex hormone inhibitor, an antispasmodic agent, a vitamin, a wound treating agent, an analgesic, an antimetabolite, a topoisomerase inhibitor, a radiosensitizer, an inhibitor of DNA repair or an α-sympathicomnimetic.
- Preferably, the photosensitive agent of the present invention is a near infrared dye selected from the group consisting of pyropheophorbide, cyclophosphamide, cyclophosphamide derivatives, bacteriochlorin (BChl) and bacteriochlorin derivatives, Cy5.5, Cy7, the hexyl ether analog of pyropheophorbide, the hexyl ether anolog of pyropheophorbide carotenoid conjugate, benzothiazole (5F203), 4-hydroperoxy-cyclophosphamide (4HC), dicarbocyanine, and, such as NIR805, Indocyanine Green (ICG) and Cypate.
- The invention also provides conjugates of 2-deoxyglucose, wherein the diagnostic or therapeutic agent is a photosensitive agent which is a photodynamic therapy agent, and preferably the photodynamic therapy agent is selected from the group consisting of a porphyrin, a chlorin, a bacteriochlorin, and derivatives thereof.
- The diagnostic or therapeutic agent of the present invention may also be an oncotherapeutic agent. The oncotherapeutic agent is preferably cyclophosphamide, 4-hydroperoxycyclophosphamide, taxol, adriamycin, or temozolomide. In a preferred embodiment, the oncotherapeutic agent is 4 hydroperoxycyclophosphamide.
- Examples of 2-deoxyglucose conjugates encompassed by the present invention are shown in
FIG. 4 . The present invention is not limited to the compounds shown inFIG. 4 , but rather these compounds are illustrative examples of conjugates encompassed herein. - The invention also provides a method of diagnosing tumor disease in an animal comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof and detecting the presence of said conjugate in the animal.
- The invention also provides a method of treating tumor disease in an animal, comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof to treat the tumor disease of the animal. In one embodiment, the tumor is a glioma.
- The invention also provides a method of treating disease in an animal using photodynamic therapy comprising administering one or more of the 2-deoxyglucose conjugates of the present invention to an animal in need thereof, followed by exposing the animal to ultraviolet, visible or infrared radiation to treat the disease of the animal. Preferably, the animal is exposed to near infrared radiation.
- The specific dose and duration of light again will depend upon the photosensitizer chosen. The fluence rate applied is preferably about 25 to about 100 mW/cm2, and most preferably about 50 to about 75 mW/cm2, while the duration of light application is about 5 to about 60 minutes, and most preferably about 20 to about 30 minutes. Suitable sources of light include commercially available lasers, lamps, light emitting diodes and the like. Preferably, LED arrays (Efos Canada, Inc., Mississauga, Ontario, Canada) are employed. To achieve the desired wavelength of light, the lamp may be equipped with commercially available filters.
- Various photosensitizers for use in the present invention are useful over the range of 350 to 1300 nm, the exact range being dependent upon the particular photosensitizer. Preferred photosensitizers are those useful in the range of 650-1000 nm (i.e., in the near infrared (“NIR”)). For example, pyropheophorbide and bacteriochlorin are useful in the 650-900 nm n range.
- It also is within the confines of the present invention that one or more quenchers can be administered before, during or after the administration of the conjugates of the present invention, but before application of light. Suitable quenchers include but are not limited to glutathione, trolox, flavonoids, vitamin C, vitamin E, cysteine and ergothioneine and other non-toxic quenchers, and preferably vitamin E. The amount of the quencher administered will depend upon the specific quencher(s) chosen and can be determined by one skilled in the art. However, when the quencher is vitamin E, the preferred dose ranges from about 10 mg/kg body weight to about 1 g/kg body weight, and most preferably about 100 mg/kg body weight. Administering one or more of the aforementioned quenchers is optional, and is complimentary to administering the conjugates of the present invention. Preferred complementary quenchers, such as vitamin E, quench free radical formation generated from a Type I photoreaction via electron transfer, and may be used as a complementary protection mechanism to quenching singlet oxygen that is generated from a Type II photoreaction via energy transfer. Nevertheless, singlet oxygen is the major cytotoxic agent responsible for PDT.
- In one embodiment of the present invention, the artificial irradiation is applied from about 5 minutes to about 3 hours after administering one or more types of conjugates of the present invention. Preferably, the artificial irradiation is applied about 10 to about 60 minutes after administering one or more kinds of conjugates of the present invention.
- The light should be applied at a sufficient wavelength, dose and duration to maximize the tumor damage, and, at the same time, to minimize the damage to the red blood cells and/or other surrounding tissue.
- In embodiments, the invention is directed to a method of inhibiting the growth of cancer cells, in vitro or in vivo, comprising contacting cancer cells with a conjugate of the present invention and, in the case of a conjugate containing a photodynamic therapy agent, exposing the cancer cells to an effective amount of artificial irradiation. In one aspect, the invention provides methods of inhibiting the growth of cancer cells, such as breast, lung, pancreas, bladder, ovarian, testicular, prostate, liver, retinoblastoma, Wilm's tumor, adrenocarcinoma or melanoma, and preferably, the cancer tumor is a prostate cancer tumor.
- In embodiments, in the methods of the present invention, the artificial irradiation is selected from the group consisting of artificial ultraviolet, infrared (IR), gamma-irradiation, x-ray and visible light. Preferably, the artificial irradiation is IR, and even more preferably, the artificial irradiation is near-infrared (NIR).
- In the methods of the present invention, in embodiments the artificial irradiation is applied about 30 minutes to about 48 hours after administering the conjugate of the present invention (e.g., by injection), and even more preferably, about 3 to about 24 hours after administering the conjugate of the present invention. Preferably, the light dose is 10 mW/cm2-100 mW/cm2.
- In a separate embodiment, in the methods of the present invention, it is preferred that the artificial irradiation be applied for about 5 seconds to about 60 minutes, even more preferred is that the artificial irradiation be applied for about 1 minute to about 45 minutes, and most preferably, in the methods of the present invention, the irradiation is applied for about 10 to about 30 minutes.
- The present invention also provides a method for curing a subject suffering from a cancer. In the cancer treating methods of the present invention, the subject may be a primate, human, ape, chimpanzee, gorilla or monkey) dog, cat, mouse, rat, rabbit, horse, goat, sheep, cow, chicken. The cancer may be identified as a breast, lung, pancreas, bladder, ovarian, testicular, prostate, liver, retinoblastoma, Wilm's tumor, adrenocarcinoma or melonoma. This method comprises administering to the subject a cancer killing amount of one or more conjugates of the present invention.
- Also provided is a method of inhibiting the proliferation of mammalian tumor cells which comprises contacting the mammalian tumor cells with a sufficient concentration of the conjugate of the invention, followed by exposure to artificial irradiation, so as to inhibit proliferation of the mammalian tumor cells.
- The subject invention further provides methods for inhibiting the growth of human tumor cells, treating a tumor in a subject, and treating a proliferative-type disease in a subject. These methods comprise administering to the subject an effective amount of the conjugate of the invention.
- It is apparent therefore that the present invention encompasses pharmaceutical compositions, combinations and methods for treating human carcinomas. For example, the invention includes pharmaceutical compositions for use in the treatment of human carcinomas comprising a pharmaceutically effective amount of the conjugate of the present invention and a pharmaceutically acceptable carrier.
- The compositions may additionally include other drugs or antibodies treating carcinomas.
- The compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspension, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application.
- The compositions of the invention also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compositions should be titrated to the individual patient. Nevertheless, an effective dose of the compositions of this invention may be in the range of from about 1 to about 2000 mg/kg. Preferably, the dosage is from about 2 to about 1000 mg/kg, more preferably, 4 to about 400 mg/kg, and even more preferably, 5 to about 100 mg/kg.
- The interrelationship of dosages for animals of various sizes and species and humans based on mg/kg of surface area is described by Freireich, E. J. et al., Cancer Chemother. 50 (4): 219-244 (1966). Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided doses may be administered daily or proportionally reduced depending on the specific therapeutic situation).
- It would be clear that the dose of the composition of the invention required to achieve cures may be further reduced with schedule optimization.
- In accordance with the practice of the invention, the pharmaceutical carrier may be a lipid carrier. The lipid carrier may be a phospholipid. Further, the lipid carrier may be a fatty acid. Also, the lipid carrier may be a detergent. As used herein, a detergent is any substance that alters the surface tension of a liquid, generally lowering it.
- In one example of the invention, the detergent may be a nonionic detergent. Examples of nonionic detergents include, but are not limited to, polysorbate 80 (also known as
Tween 80 or (polyoxyethylenesorbitan monooleate), Brij, and Triton (for example Triton WR-1339 and Triton A-20). - Alternatively, the detergent may be an ionic detergent. An example of an ionic detergent includes, but is not limited to, alkyltrimethylammonium bromide.
- Additionally, in accordance with the invention, the lipid carrier may be a liposome. As used in this application, a “liposome” is any membrane bound vesicle which contains any molecules of the invention or combinations thereof.
- The amount of conjugate administered in the formulation will depend upon the photosensitizer chosen. Preferably, the amount of conjugate administered is about 0.1 to about 10.0 mg/kg body weight of the subject, more preferably about 0.3 to about 6 mg/kg body weight, and even more preferably, 0.4-4.0 mg/kg body weight.
- In embodiments, in the methods of treating cancer of the present invention, the artificial irradiation is applied for about 10 seconds to about 60 minutes, and even more preferably, the artificial irradiation is applied for about 15 seconds to about 30 minutes.
- In a separate embodiment, the present invention further provides pharmaceutical compositions which comprise the conjugates of the present invention and a pharmaceutically acceptable carrier.
- The present invention further provides a method of treating cancer in a subject cancer comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention.
- The antineoplastic agents of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences (16th ed., Osol, A., Ed., Mack, Easton Pa., 1980). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the compound, together with a suitable amount of carrier vehicle.
- A composition is said to be “pharmacologically acceptable” if its administration can be tolerated by a recipient patient. Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
- “Administering” refers providing at least one pharmaceutical agent to a subject. Thus, “administering” includes oral administration, administration as a suppository, topical contact, intravenously, intraperitoneally, intramuscularly, subcutaneously, intranasally, enterally, parenterally, implantation of a slow release device such as a miniosmotic pump, and inhalation. When administering by injection, the administration may be by continuous infusion, or by single or multiple boluses.
- In providing a mammal, and particularly a human, with therapeutic agents, the dosage will vary depending upon such factors as the recipient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage in the range of from about 1 pg/kg to about 10 mg/kg (body weight of recipient), although a lower or higher dosage can be administered. The dosage frequency can be repeated at intervals ranging from each day to every other month.
- The compounds of the present invention are intended to be provided to recipient subjects in an amount sufficient to induce a therapeutic effect. An amount is said to be sufficient to induce a therapeutic effect if the dosage, route of administration, etc. of the agent are sufficient to reduce, attenuate, or stop tumor progression.
- The compounds of the invention may be administered either alone or in combination with additional therapeutic agents. The administration of such agent(s) may be for either a “prophylactic” or “therapeutic” purpose. When provided prophylactically, the agents are provided in advance of any tumor detection. The prophylactic administration of the compound(s) serves to prevent or attenuate any tumor formation. When provided therapeutically, the agent(s) is provided at (or shortly after) the detection of actual tumor formation.
- The compositions of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, are described, for example, in Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Pub., Easton, Pa., 1990.
- “Pharmaceutically acceptable carrier” includes any material which when combined with a therapeutic agent, retains the therapeutic agent's activity and is nonreactive with the mammal's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets, including coated tablets, and capsules. Typically, such carriers contain excipients, such as starch, milk, sugar certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods.
- Additional pharmaceutical methods may be employed to control the duration of action. Control release preparations may be achieved through the use of polymers to complex or absorb therapeutic agents. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate the therapeutic agent(s) into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, the therapeutic agent(s) can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin micro spheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Publ., Easton, Pa. (1990).
- The present invention also provides methods of making the compounds of the present invention. In embodiments, the present invention provides a method of making 2-deoxyglucose derivatives of the diagnostic and therapeutic agents of the present invention.
- In particular embodiments, the synthesis of a 2-deoxyglucose derivative of pyropheophorbide is provided. For example, to synthesize the desired Pyro-2DG, pyropheophorbide is first treated with N-hydroxysuccinimide in the presence of DCC. The pyropheophorbide succinimidyl ester so obtained is then reacted with activated D-glucosamine to yield the desired conjugate in 50% overall yield (see
Scheme 1′). In embodiments, activated D-glucosamine is produced by treating D-glucosamine hydrochloride with sodium methoxide. - In further embodiments, an amine reactive universal linker, such as isothiocyanate, is introduced into the bacteriochlorophyll (BChl) macrocycle allowing bioconjugation of these NIR dyes with biologically important molecules such as peptides, metabolites, proteins, and other affinity ligands.
- In further embodiments, the synthesis of bacteriochlorin e6 isothiocyanate (BChlE6-NCS) is also provided. BChlE6-NCS can subsequently be conjugated to a 2-deoxyglucose moiety to form bacteriochlorin e6 2-deoxyglucosamide. Specifically BOC-protected amino-bacteriochlorin e6 (BChlE6-BOC) is formed from bacteriopheophorbide as described in more detail below. The bacteriopheophorbide a methyl ester is then used to produce amino-bacteriochlorin e6 (BchlE6-NH2) and bacteriochlorin e6 isothiocyanate (BChlE6-NCS), which is then conjugated to form BChlE6-2DG.
- The examples below explain the invention in more detail. The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. The present invention, however, is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only, and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
- Materials and General Methods. Melting points are uncorrected. UV-vis spectra were recorded on a Beckman DU-600 spectrophotometer. Fluorescence emission was measured with a Perkin-Elmer LS-50B fluorometer. 1H NMR spectra were recorded on a Bruker ASPECT 360 M instrument. ESI-MS and HRMS spectrometric analysis were performed at the Mass Spectrometry Facility of the Department of Chemistry, University of Pennsylvania. Methyl pheophorbide a was isolated from Spirulina pacifica algae available from Cyanotech Corp., Hawaii. Pyropheophorbide (1) was synthesized from methyl pheophorbide according to literature procedures (Zheng, G., Li, H., Zhang, M., Chance, B., and Glickson, J. D. (2002) Low-density Lipoprotein Reconstituted by Pyropheophorbide Cholesteryl Oleate as Target Specific Photosensitizer Bioconjugate Chem. 13, 392-396). Other chemicals were purchased from Aldrich. When necessary, solvents were dried before use. For TLC, EM Science TLC plates (silica gel 60 F254) were used. Reverse phase (RP) analytical HPLC was performed using a Zorbax RX-C8 (9.4 mm×250 mm) column eluting at 1.0 mL/min with MeCN/phosphate buffer (0% to 99% MeCN gradient) with UV-vis detection at 414 nm.
- Pyropheophorbide succinimidyl ester (2): Pyropheophorbide (1) (208 mg 0.39 mmol) was activated with DCC (80 mg 0.39 mmol) and N-hydroxysuccinimide (92 mg 0.8 mmol) in 10 mL DMF. After stirring for 24 h, urea was filtered off, and solvents were removed. The crude product was purified by column chromatography (silica gel 60) and eluted with 5% methanol in CH2Cl2. The desired product was crystallized from CH2Cl2/hexane in 80% yield (195 mg 0.31 mmol). Mp: 200-202° C. UV-vis in CH2Cl2: 413 nm (ε1.1×105), 509 (1.2×104), 538 (1.0×104), 609 (8.7×103) and 666 (5.0×104). Mass calculated for C37H37N5O5: 631.7; found by ESI-MS 632.7) and 654.6 (M+Na+). 1H NMR (CDCl3, δ ppm): 9.42, 9.31 and 8.56 (each s, 1H, 5-H, 10-H and 20-H); 7.95 (dd, J=17.8, 11.8 Hz, 1H, 31-CH═CH2); 6.25 (d, J=17.8 Hz, 1H, trans-32-CH═CH2); 6.14 (d, J=11.8 Hz, 1H, cis-32-CH—H2); 5.17 (ABX, 2H, 132-CH2); 4.49 (d, J=7.2 Hz, 1H for 18-H); 4.40 (m, J=7.2 Hz, 1H for 17-H); 3.63 (s, 5H, 8-CH2CH3, 12-CH3); 3.40 and 3.18 (each s, 3H, 2-CH3 and 7-CH3); 2.87 (br, 5H, 171-H and succinimide-CH2CH2—); 2.62 and 2.27 (each m, 1H, for 2×172-H); 1.93 (m, 1H for 171-H); 1.82 (d, J=7.2 Hz, 3H, 18-CH3); 1.70 (t, J=7.2 Hz, 3H, 8-CH2CH3); 1.33 and 1.12 (each brs, 1H, 2×N—H).
- Pyropheophorbide-2-deoxyglucosamide (Pyro-2DG) (3): D-Glucosamine hydrochloride (130 mg 0.6 mmol) was added to a solution of sodium methoxide (32.4 mg 0.6 mmol) in 7 mL DMSO. The mixture was stirred for 2 h, and pyropheophorbide succinimide ester (2) (190 mg 0.3 mmol) was added. The reaction mixture was stirred under argon atmosphere for 20 h. After removing solvents, the crude product was washed with dichloromethane, water and crystallized from methanol. The title compound was obtained in 102 mg yield. The filtrate was further concentrated and purified by silica gel plate chromatography (20% methanol in dichloromethane), 30 mg more of Pyro-2DG was obtained. Thus, the total product yield is 63% (132 mg, 0.19 mmol). Mp: >200° C. Analytical RP HPLC: Rt 20.9 min, 99.5%. UV-vis in DMSO: 415 nm (ε1.2×105), 510 (1.2×104), 540 (1.0×104), 611 (8.6×103) and 668 (5.0×104). Mass calcd for C39H45N5O7: 718.3217 (M+Na+), found by HRMS: 718.3249 (M+Na+). 1H NMR (DMSO-d6): 8.97, 8.70 and 8.69 (each s, 1H, 5-H, 10-H, and 20-H); 7.97 (dd, J=17.7, 11.8 Hz, 1H, 3′-CH═CH2); 6.15 (dd, 2H, J=17.7 Hz, 1H, trans-32-CH═CH2, J=5.4 Hz, α-H); 5.97 (d, J=11.8 Hz, 1H, cis-32-CH═CH2); 4.98 (ABX, 2H, 132-CH2); 4.81-4.35 (each m, total 5H, sugar-H); 4.18 (br, 1H for 18-H); 4.11 (d, J=7.2 Hz, 1H for 17-H); 3.68 (q, J=7.4 Hz, 21H, 8-CH2CH3); 3.58, 3.43 and 3.16 (s, each 3H, 12-CH3, 2-CH3 and 7-CH3); 2.59 (m, 1H, 171-H); 2.50 (m, 2H, 172-H); 2.12 (m, 1H, 171-H) 1.80 (d, J=7.2 Hz, 3H, 18-CH3); 1.59 (t, J=7.2 Hz, 3H, 8-CH2CH3).
- Confocal Microscopic Studies: 9L glioma cells were grown for 5 days in 4-well Lab-Tek chamber slides (Naperville, Ill.). Before the cell experiments, the culture medium was replaced by preincubation medium (medium with 1% (w/v) BSA instead of PBS). The cells were washed three times with preincubation medium (for 15, 15, and 30 min), and cultured in this medium for a further 20 hours. Experiments were started, after two quick washes with preincubation medium, by the addition of preincubation medium containing the indicated amounts of Pyro-2DG and/or D-Glucose. After 30 minutes incubation at 37° C., the cells were washed five times with ice-cold PBS containing 0.8% BSA, two times with PBS alone, and fixed for 20 minutes with 2% formaldehyde in PBS at room temperature. Then the chamber slides were mounted and sealed for confocal microscopic analysis.
- Animals: Rat 9L glioma was implanted on the flanks of male Fisher 344 rats (150-200 g) via subcutaneous injection of 0.1 mL, ˜106 9L glioma cells. Within ten days, tumors grew to the desired size of 1 cm in diameter. After not feeding animals for 24 hours, the rats were anaesthetized via intraperitoneal injection of Ketamine (75 mg/kg) and Xylazine (10 mg/kg). Pyro-2DG (2 mL, concentration: 0.25 mg/mL) was injected via tail vein infusion over a period of 1 hour (dose: 2.5 mg/kg). Thirty minutes later, the rats were anesthetized again and subjected to PDT.
- PDT Protocol: A “point treatment” protocol was designed for evaluating PDT response of Pyro-2DG. PDT was carried out using a KTP YAG pumped dye module (Laserscope, San Jose, Calif.) tuned to produce 670 nm light. Light delivery was through a 1 mm fiber to create a treatment spot of 0.96 mm in diameter when the fiber was held closely adjacent to the tumor. The light field was fixed in position at the center of the tumor by mounting the fiber in the center of a circular plate which was glued to the anesthetized animal. The light was delivered at a fluence rate of 75 mW/cm2 to a total dose of 175 J/cm2. Laser power output was measured with a power meter (Coherent, Auburn, Calif.).
- Fluorescence Imaging of Tumors (Quistorff, B., Haselgrove, J. C., and Chance, B. (1985) High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal. Biochem. 148, 389-400; Gu, Y. Q., Qian, Z. Y., Chen, J. X., Blessington, D., Ramanujam, N., and Chance, B. (2002) High-resolution three-dimensional scanning optical image system for intrinsic and extrinsic contrast agents in tissue. Rev. Sci. Instruments 73, 172-178; Ramanujam, N., Richards-Kortum, R., Thomsen, S., Mahadevan-Jansen, A., Follen M., and Chance B. (2001) Low temperature fluorescence imaging of freeze-trapped human cervical tissues. Opt.
Express 8, 335-343): Immediately after PDT, animals were immersed in pre-cooled isopentane (−150° C.) and transferred to liquid nitrogen (−196° C.) 5 minutes later. Tumors were then surgically excised, embedded in a mixture of ethanol-glycerol-water (freeze point: −30° C.), and mounted at low temperature for 3D surface fluorometric scanning. Thus, the frozen tumor sample was milled flat and imaged every 100 μm from the top surface to the bottom of the tumor. The light guide (fused silica, 50 μm core diameter) stepped across the tissue surface at a fixed distance from the tissue surface (70 μm). The imaging resolution of the low temperature scanning fluorometer was 80 μm. The fluorescent signals of FP (filters: Ex: 440DF20, Em: 520DF40), PN (filters: Ex: 365HT25, Em: 455DF70), Pyro-2DG (filters: Ex: 405DF40, Em: 700ALP) were imaged for each depth of tumor. The scanning was performed at 128×128 steps that could cover 1.024×1.024 cm2. The fluorescence signal was automatically digitized and recorded on a PC. The redox ratio of PP/(FP+PN) was calculated with MATLAB. - To synthesize the desired Pyro-2DG, the pyropheophorbide was first treated with N-hydroxysuccinimide in the presence of DCC. The pyropheophorbide succinimidyl ester (2) so obtained was reacted with D-glucosamine that was activated by treating D-glucosamine hydrochloride with sodium methoxide to yield the desired conjugate (3) in 50% overall yield (see
Scheme 1′). The structures of all new compounds were confirmed by HRMS and NMR spectroscopy. The HPLC chromatograms of the final conjugate confirmed its homogeneity. - Despite containing the hydrophilic 2DG moiety, Pyro-2DG is only partially water-soluble due to the hydrophobic nature of the porphyrin macrocycle. Formulation with detergent (1% Tween 80) made it completely miscible with water and suitable for in vivo administration. A “point treatment” protocol for evaluating PDT response of Pyro-2DG was designed. Instead of irradiating the whole tumor area (1 cm in diameter), only an area ˜1 mm in diameter at the center of the tumor was treated. The same laser power and light dose (75 mW/cm2, 175 J/cm2) were used throughout the experiments. Based on the absorption and emission maxima of Pyro-2DG (λex=665 nm; λem=720 nm), the 9L tumor was treated with 670 nm laser light, and a 700 nm long pass filter was incorporated into the 3D fluorescence scanner for collecting the Pyro-2DG fluorescence at 720 nm. This point treatment procedure is designed for two purposes: 1) to allow the adjacent untreated tumor region along with the normal tissue region to serve as internal controls; and 2) to evaluate possible bystander effects.
- The tumor specificity of Pyro-2DG is, of course, limited by uptake of glucose by various normal tissues; however, most tumors consume substantially more glucose than the surrounding normal tissues. Thus, all PDT experiments were carried out under fasting conditions. Low serum glucose levels were achieved by not feeding animals for 24 hour before the experiments. Moreover, the animals were given low concentration Pyro-2DG via tail vein infusion over a period of 1 hour to enhance the tumor uptake. Thirty minutes after injection, the animals were subjected to the PDT (75 mW/cm2, 175 J/cm2). After PDT, animals were rapidly frozen and kept in liquid nitrogen for fluorescence imaging studies using the low temperature 3D scanning fluorometer.
- This fluorometer was designed originally to examine the redox state of in-vivo-freeze-trapped tissue (Quistorff, B., Haselgrove, J. C., and Chance, B. (1985) High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal. Biochem. 148, 389-400). It detects the intrinsic fluorescence of oxidized flavoprotein (FP, λex: 436 nm, λem: 560 nm) and reduced pyridine nucleotide (PN, λex: 366 nm, λem: 450 nm) stemming from mitochondria. The PN signal indicates mainly NADH, whereas the PP signal originates from the flavins of dehydrolipoamide dehydrogenase component of pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. Because 1) the flavoproteins are coupled to the mitochondrial NAD/NADH redox system by pyruvate dehydrogenase and α-ketoglutarate dehydrogenase reactions, and 2) only the reduced form of the PN system and the oxidized species of PP couple are strongly fluorescent, the ratio of FP/(FP+PN) calculated from FP and PN signals accurately represents the redox state of the mitochondrial NAD/NADH redox couple (Chance, B., Schoener, B., Oshino, R., Itshak, P., and Nadase, Y. (1979) Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-Trapped Samples. J. Biol. Chem. 254, 476-44771). Thus, the redox ratio can be used to evaluate the PDT damage to the tumor mitochondria. In addition to monitoring the fluorescence of endogenous PN (NADH) and FP, this fluorometer is also useful in detecting any exogenous fluorophore (e.g. Pyro-2DG) that is present in the specimen.
- There are some distinctive advantages of this freeze-quenching technique (Quistorff, B., Haselgrove, J. C., and Chance, B. (1985) High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal. Biochem. 148, 389-400, Chance, B., Schoener, B., Oshino, R., Itshak, F., and Nadase, Y. (1979) Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-Trapped Samples. J. Biol. Chem. 254, 476-44771). First, it stops metabolic processes, providing a “snap shot” of metabolism at the moment of freezing and also allowing a 3D analysis by means of reflectance spectrophotometric imaging of successive slices through the frozen tissue block. Furthermore, the fluorescence quantum yield is typically 5- to 10-fold higher at liquid nitrogen temperature, vastly improving the signal-to-noise ratio. Also, because of the complete arrest of metabolic processes, the time taken for the analysis is not of importance. This facilitates high resolution scanning with signal/noise enhancement through signal averaging. Using this technique, we have studied fluorescence images of PP, PN (NADH) and Pyro-2DG on animals with or without PDT treatment. The results are discussed below:
-
FIG. 1 shows the redox ratio images (the first column), their corresponding histograms (the second column) and the Pyro-2DG fluorescence images (the third column) of 9L glioma and surrounding muscle tissue. The x and y axes of images represents the number of pixels scanned, whereas x and y axes of the histograms represents the relative redox ratio value and its corresponding pixel number, respectively. As shown inFIG. 1 , Pyro-2DG is selectively accumulated inside the tumor margin (top row images) compared to surrounding normal tissue such as muscle (middle row images), and there is no background fluorescence observed from the control experiment in which tumor is imaged in the absence of Pyro-2DG (bottom row images). This study also demonstrates that the tumor control (tumor alone) and the drug control (Pyro-2DG+tumor) exhibit similar redox states since similar FP and PN signals and similar PP/(FP+PN) ratios were detected in both instances. This indicates that the addition of Pyro-2DG has no effect on the mitochondrial activities of the tumor in the absence of light. - Upon PDT treatment, Pyro-2DG dramatically altered the redox state of the tumor. As shown in
FIG. 2 , the irradiated spot (indicated by a cross) exhibited a marked increase in PP fluorescence (red region in the center of tumor, see the first image of the top row) and a significant decrease in NADH fluorescence (see the second image of the top row). This produced a dramatic increase in the redox ratio of the tumor [FP/(FP+PN), see the third image of the top row]. Since the ratio of FP/(FP+PN) represents the redox state of the mitochondrial NAD/NADH redox couple, the significant enhancement of this ratio clearly reflects the extensive mitochondrial damage (oxidation) experienced by the irradiated region of the tumor, but not the adjacent unirradiated region. Strikingly, the complete disappearance of the Pyro-2DG fluorescence signal was observed in the same region (there is a dark “hole” at the center of the tumor, see the last image of the top row), indicating selective photobleaching of the photosensitizer. Since PDT is mediated by the production of reactive oxygen species resulting in cell kill via oxidation (22), there is a direct correlation between the selective photobleaching of the Pyro-2DG and the selective tumor destruction stemming from the oxidation of tumor mitochondria. In order to verify that such tumor destruction is caused by the photodynamic action of the Pyro-2DG, a PDT control experiment was conducted by not injecting the photosensitizer. As shown inFIG. 2 (see the bottom row images), there is little or no change in the redox ratio in the absence of Pyro-2DG; this experiment, therefore, clearly demonstrates that the PDT response is due to Pyro-2DG′ photosensitization. - To determine the specificity of Pyro-2DG toward GLUTs, confocal fluorescence microscopy studies were performed. As shown in
FIG. 4 , Pyro-2DG localizes within 9L glioma cells at 37° C. and that localization was competitively inhibited by D-glucose. In contrast to Pyro-2DG, uptake of pyropheophorbide a in 9L glioma cells is concentration dependent and is not inhibited by D-glucose, indicating that its uptake is GLUT-independent (data not shown). This study suggests that Pyro-2DG is delivered and trapped in tumor cells via the GLUT/hexokinase pathway. - In conclusion, a new photosensitizer targeted at the GLUT pathway to serve as both a targeted PDT agent and a NIR imaging agent has been designed and synthesized. Following intravenous administration to 9L glioma bearing animals, Pyro-2DG selectively accumulated in the tumor compared to the surrounding normal tissue as observed by measuring its NIR fluorescence at 720 nm using a low-temperature 3D fluorescence scanner. Upon PDT treatment of this tumor, this agent efficiently causes selective mitochondrial damage to the region of a tumor that was photoirradiated after administration of this agent, but does not affect tissues photoirradiated in the absence of the agent or tissues treated with the agent that are not photoirradiated. The confocal microscopy data are consistent with the hypothesis that Pyro-2-DG has been delivered and trapped in tumor cells via the GLUT/hexokinase pathway, and therefore, Pyro-2DG is useful both as a tumor-selective NIR fluorescence imaging probe and as a PDT agent.
- Materials
- All 2-deoxyglucose conjugates, including pyropheophorbide 2-deoxyglucosamide (Pyro-2DG) (Zhang, M., et al., Bioconjugate Chemistry 14:709-714 (2003)), two bacteriochlorophyll 2-deoxyglucosamides (BChlPP-2DG and BChlE6-2DG), dicarbocyanine 2-deoxyglucosamide (NIR6642DG) and two tricarbocyanine 2-deoxyglucosamides (NIR805-2DG and Cypate-2DG), were synthesized in our molecular imaging chemistry laboratory of the Department of Radiology at the University of Pennsylvania. All fluorophores were prepared in-house, except the Cypate (Achilefu, S., et al., J. Med. Chem. 45:2003-2015 (2002)), which is a generous gift by Dr. Achilefu of the Washington University Medical School.
- Confocal Microscopic Studies
- 9L glioma cells, obtained from Department of Radiation Oncology at University of Pennsylvania, were cultured in Modified Eagle's Medium (MEM) supplemented with 15% newborn calf serum (NCS), 100 U/ml penicillin-streptomycin. Murine melanoma B16 cells, obtained from Dr. Theo van Berkel's laboratory at the University of Leiden, Netherlands, were cultured in Dulbeco's modified Eagle's medium (DI) supplemented with 10% fetal bovine serum SOBS) and 100 U/n-d penicillin-streptomycin Cells were grown at 37° C. in an atmosphere of 5% CO2 in a humidified incubator. Cells were grown for 5 days in Swell Lab-Tek chamber slides (Naperville, Ill.) before the experiment. Indicated amounts of NIRF-2DGs with or without D-Glucose and Rbodarninc-123 were incubated with 9L glioma cells/B16 melanoma cells at 37° C. for 30 min after 3 washes with Dulbecco's Phosphate Buffered Saline (D-PBS). After incubation, the cells were washed five times with ice-cold PBS and Fixed for 20 minutes with 2% formaldehyde in PBS at room temperature. Then the chamber slides were mounted and sealed for confocal microscopic analysis. Confocal aticroscopic images were obtained with TCS SPII laser scanning confocal microscope (LSCM) (Heidelber, Germany).
- Tumor Bearing Animal Models
- Two tumor bearing animal models were used for this study. 9L glioma bearing rat model was obtained by implanting 2×106 Cells in the flank of male Fisher 344 rats (150-200 g) via subcutaneous injection. Animals were studied when tumor size reached 2 cm×1.8 cm. To facilitate the in vivo NM imaging using Palomar Imager, KB tumor (squamous cell carcinoma) bearing nu/nu mouse model was also used. The average tumor size was 0.8 cm×0.8 cm.
- Sample Preparation for Fluorescent Cryo-Imaging
- The 9L glioma-bearing rat was anaesthetized intraperitoneally by injecting Ketamine (75 mg/kg) and Xylazine (10 ing/kg) and was given Pyro-2DG (1 mL, concentration: 0.5 mg/ml) via tail vein injection within 2 min. After 2 hirs, the rat was immersed in pre-cooled isopentane (−150° C.) and transferred to liquid nitrogen (−196° C.) 5 minutes later. Tumors and the surrounding muscle tissues were then surgically excised, embedded in a mixture buffer (ethaiiol-glycerol-water, freeze point: −30° C.), and mounted for fluorescent Cryo-imaging.
- Fluorescent and redox ratio imaging of tumors with the Cryo-Imager (Quistorff, B., et al., Analytical Biochemistry 14&389-400 (1985))
- The frozen tumor sample was ground flat and then further ground to obtain images every 100 μm from the top surface to the bottom of the tumor. A bifurcated optical fiber bundle (7 quartz fibers, 70 pi core diameter for each, 0.34 numerical aperture, 1 fiber for emission in center, 6 fibers for excitation around the emission fiber) stepped across the tissue surface at a fixed distance. The excitation filter and the emission filter for detecting the fluorescent signals of each substance were designed based on the absorption and emission spectra of each fluorophores (See
FIG. 1 ). Using a Mercury Arc lamp as the excitation light source, the fluorescent signals of oxidized flavoprotein (Fp, filters: Ex: 44ODF20, Em: 52ODF40), reduced pyridine nucleotide (PN, filters; Ex: 365HT125, Em: 455DF70) were also obtained for each depth of the tumors. The redox ratio of PN/(Fp+PN) and Fp/(FP+PN) calculated with MATLAB represented the reduced state and oxidized state of the mitochondria, respectively. The scanning was performed at 128×128 steps that covered 1,024×1.024 cm2 area (80 μm in-plane resolution). - In vivo real time fluorescent imaging of tumors with the Palomar™ Imager (Benaron, D. A., et al., Molecular Imaging 2:S194 (2003))
- NIR805-2DG probe (100 μL of 1 μM) was administered intravenously to the nu/nu mice with KB tumors. A series of real time Palomar™ images were taken at different time points. The Palomar Imager, developed by the Spectros Corp., CA, is a flexible system designed for imaging the distribution and localization of targeted fluorescent agents in small animals and humans in room light surgical operating room conditions.
- Results and Discussion
- For this study, we have synthesized a series of NIRF-2DG conjugates by replacing the [18F] atom at the 2-position of the FDG with fluorophores based on either tetrapyrrole dyes or cyanine dyes. These imaging agents are pyropheophorbide 2-deoxyglucosamide Pyro-2DG), two bacteriochlorin 2-deoxyglucosamides (BChlPP-2DG and BChlE6-2DG), dicarbocyanine 2-deoxyglucosamide (NIR664-2DG) and two tricarbocyanine 2-deoxyglucosamides, NIR805-2DG and Cypate-2DG.
- In Vitro Fluorescence Studies
- It is well known that the mechanism of 18FDG accumulation in tumors is similar to that of native D-glucose since [18F] atom of the FDG is very similar to the native 2-OH group of the glucose size wise. To our strategy, the first question needs to be answered is that, will replacement of [18F] with a much larger fluorophore moiety affect its GLUT transportation and the subsequent hexokinase mediated phosphorylation reaction? Or using a metaphor, will the “mouse” be able to drag an “elephant” through a mouse hole? To determine whether NIRF-2DG was transported through GLUTs, laser confocal microscopy was first used to demonstrate and quantify the uptake and localization of Pyro-2DG, which has a neutral porphyrin fluorophore, in 9L glioma cells. As shown in
FIG. 5 , Pyro-2DG localizes within 9L glioma cells at 37° C. and localization was competitively inhibited by D-glucose. In contrast to Pyro-2DG, uptake of pyropheophorbide a in 9L glioma cells is concentration dependent and is not inhibited by D-glucose, indicating that its uptake is GLUT-independent. Thus, Pyro-2DG uptake by 9L glioma cells appears to be through the active-transport mechanism. To farther determine the subcellular localization of Pyro-2DG, we performed the confocal imaging of 9L glioma cells incubated with both Pyro-2DG and Rhodamine 123, a well-known mitochondria tracker. As shown inFIG. 6 below, the results clearly demonstrated that Pyro-2DG localized in mitochondria. - The same question was asked for other 2-deoxyglucose fluorescent probes, and especially those have charged cyanine fluorophores. To examine the effect of structural difference of different fluorophores on the tumor uptake, similar confocal imaging studies were performed for NIR6642DG.
FIG. 7 demonstrated that NIR664-2DG localized within B16 melanoma cells, another GLUTs overexpression tumor line, at 37° C. after 20 minutes incubation, and that localization was competitively inhibited by D-glucose. Thus, cyanine dye based NIRF-2DG probes appear to enter the cells via the same uptake mechanism as do the neutral porphyrin-based NIR-2DG probes. Low temperature fluorescence imaging studies using Cryo-imager. To test these new probes in animal models, surface fluorescence scanning was performed on all probes using a high-resolution low temperature fluorometer (Cryo-imager) and all compounds were found to selectively accumulate in animal tumors.FIG. 8 illustrated that Pyro-2DG accumulated preferentially in the 9L glioma tumors of fasted rats relative to adjacent skeletal muscle at a ratio of 10:1. - In order to determine the biodistribution of the Pyro-2DG, a normal Fisher 344 rat was sacrificed and different organs were scanned for Pyro-2DG fluorescence with Cryo-
imager 1 hour after Pyro-2DG was intravenously administered. The preliminary results shown inFIG. 9 indicated that Pyro-2DG accumulated predominantly in liver, with lesser accumulation in spleen and kidney, and does not cross the blood-brain barrier. - In Vivo Real Time Imaging of Tumors with NIRF-2DG.
- An in vivo real time tumor imaging study was performed in bright room light using Spectros' Palomar Optical Contrast system. This is a flexible system designed for imaging the distribution and localization of targeted fluorescent agents in humans and small animals in room light surgical operating room conditions. The images were displayed with 1 second update speed, including all processing/colorization of tumor fluorescence overlaid on a black and white background image. Thus, NIR805-2DG probe (100 μL of 1 μM) was administered intravenously to the nu/nu mice with KB tumors (squamous cell carcinoma) and a series of real time Palomar images were taken at different time points (see
FIG. 10 ). At 10 min post-injection, the fluorescent signal glows everywhere, with a signal forming slightly then strongly over the liver with no localized signal con-Ling from the tumor (T). There is no signal at the tumor, in part due to the scaling of the image (since too much signal everywhere, so scale is raised to see only the liver outline). After 1 hr, the signal is primarily over the liver. By 4 hours, the dorsal tumor glows brightly, and there is less dye signal from the liver. At 1 day, there is a large amount of signal in the gut (G) in the abdomen, but tumor signal still was observed. This study clearly demonstrated that the utility of NIRF-2DG as NIR fluorescent imaging agents for the detection of tumor in vivo. - In conclusion, a series of new NIR fluorescent imaging and PDT agents targeting at the GLUT pathway have been designed and synthesized. Both the in vitro confocal microscopy data and the in vivo imaging studies confirmed that both porphyrin and cyanine dye-based 2-deoxyglucose conjugates are tumor selective. In conjunction with using these new imaging probes, the NIR fluorescence imaging and photodynamic therapy method described earlier provides a prospective high sensitive technology for detecting and treating subsurface cancers at an early stage, thus providing a facial transition between cancer detection and treatment.
- Materials and General Methods. Melting points are uncorrected. UV-vis spectra were recorded on a Beckman DU-600 or a Perkin-Elmer Lambda spectrophotometer. Fluorescence emission was measured with a Perkin-Elmer LS-50B fluorometer. 1H NMR spectra were recorded on a Bruker ASPECT 360 MHz instrument. ESI-MS and HRMS spectrometry analysis were performed at the Mass Spectrometry Facility of the Department of Chemistry, University of Pennsylvania. Methyl pheophorbide a was obtained from Spirulina pacifica algae available from Cyanotech Corp., Hawaii. Purpurin-18 methyl ester (1) was synthesized from methyl pheophorbide according to a literature procedure. (Zheng, G.; Li, H.; Zhang, M.; Lund-Katz, S.; Chance, B.; Glickson, J. D., Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjugate Chemistry 2002, 13, (3), 392-396.) Bacteriochlorophyll a (BChl) was extracted from R Sphaeroides biomass purchased from Frontier Science, Utah. Bacteriopurpurin-18 methyl ester (6) and bacteriopheophorbide a methyl ester (11) were synthesized from BChl according to previously described procedures. (Kozyrev, A. N.; Zheng, G.; Zhu, C. F.; Dougherty, T. J.; Smith, K. M.; Pandey, R. K., Syntheses of stable bacteriochlorophyll-a derivatives as potential photosensitizers for photodynamic therapy. Tetrahedron Letters 1996, 37, (36), 6431-6434; Hartwich, G.; Fiedor, L.; Simonin, I.; Cmiel, E.; Schafer, W.; Noy, D.; Scherz, A.; Scheer, H., Metal-substituted bacteriochlorophylls. 1. Preparation and influence of metal and coordination on spectra. Journal of the
American Chemical Society 1998, 120, (15), 3675-3683). Other chemicals were purchased from Aldrich. Where necessary, solvents were dried before use. For TLC, EM Science TLC plates (silica gel 60 F254) were used. Purity of the final conjugates was validated by reverse phase HPLC using a Waters Delta-600 analytical/semi-preparation system equipped with photodiode array and fluorescence detectors. - Purpurin-18-N-3′-(BOC-amino)propylimide, PP18-BOC (2): Purpurin-18 methyl ester (1) (200 mg, 0.346 mmol) and tert-Butyl N-(3-aminopropyl)-carbamate (380 mg, 2.18 mmol) were dissolved in 15 mL benzene. The mixture was refluxed at 78° C. under argon atmosphere for 48 hrs. After removing solvent, the crude residue was purified by silica gel column chromatography with 5% MeOH in CH2Cl2. The desired product was obtained in 75% yield (190 mg). UV-vis in CH2Cl2 λmax: 367 nm (e: 5.3×104), 419 (1.3×105), 550 (2.2×104), 662 (9.4×103) and 706 (4.1×104). Mass calculated for C42H50N6O6: 734.4; found by ESI-MS; 757.8 (M+Na)+. 1H NMR (CDCl3, δ ppm): 9.27, 9.07 and 8.55 (each, s, 1H, for 10, 5 and 20-H), 7.75 (dd, 1H), 6.17 (d, 1H), 6.06 (d, 1H), 5.72 (brs, 1H), 5.38 (d, 1H), 4.59 (t, 2H), 4.38 (m, 1H), 3.65 and 3.63 (each, s, 3H), 3.37 (m, 4H), 3.29 and 2.94 (each, s, 3H), 2.86 (m, 1H), 2.46 (m, 2H, 1H), 2.21 (m, 2H), 2.00 (m, 1 μl), 1.80 (d, 3H), 1.54 (s, 12H), −0.2 and 40.31 (each brs, 1H, 2×NH).
- Purpurin-18-N-3′-(isothiocyanate)propylimide, PP18-NCS (4): Purpurin-18-N-3′-(BOC-amino)propylimide (190 mg, 0.259 mmol) was dissolved in 3 mL TFA. The mixture was subsequently stirred at room temperature under argon atmosphere. One hour later, TFA was removed by vacuum. The crude residue was diluted with 40 mL CH2Cl2, and then washed with 30 mL NaHCO3 and 2×30 mL water. The organic layer was dried over anhydrous Na2SO4. After removing solvent, purpurin-18-N-3′-(amino)propylimide (3) was obtained in 140 mg (yield 86%). It was then used directly for the next reaction without further purification. This intermediate (140 mg, 0.22 mmol) and 1,1′-thiocarbonyldiimidazole (43 mg, 0.243 mmol) were dissolved in 10 mL CH2Cl2. The reaction mixture was refluxed at 40° C. under argon atmosphere for 3 hrs. After removing solvent, the crude obtained was purified by silica gel plate with 2% MeOH in CH2Cl2. The desired isothiocyanate product was obtained in 75% yield (110 mg). UV-vis in CH2Cl2 λmax: 367 nm (ε: 4.8×104), 418 (1.5×105), 550 (1.0×104), 649 (2.4×103) and 706 (5.5×104). Mass calculated for C38H40N6O4S: 699.2729 (M+Na)+; found by HRMS: 699.2691 (M+Na)+. 1H NMR (CDCl3, δ ppm): 9.56, 9.32 and 8.56 (each s, 1H, for 10, 5 and 20-H), 7.87 (dd, 1H), 6.27 (d, 1H), 6.15 (d, 1H), 5.31 (d, 1H), 4.60 (t, 2H), 4.35 (m, 1H), 3.87 (t, 2H), 3.85 (s, 3H), 3.65-3.55 (m, 5H,), 3.34 and 3.13 (each s, 3H), 2.75 (m, 1H), 2.40 (m, 4H), 1.97 (m, 1H), 1.76 (d, 3H), 1.65 (t, 3H), 0.08 (m, 2H, 2×NH.
- Preparation of 2-deoxyglucose conjugate of Purpurin-18-N-3′-(isothiocyanate)propylimide, PP18-2DG (5): D-Glucosamine hydrochloride (13 mg, 0.06 mmol) was added to a solution containing sodium methoxide (3.24 mg, 0.06 mmol) in 3 mL DMSO. The reaction mixture was stirred at room temperature for 2 hrs, and purpurin-18-N-3′-(isothiocyanate)propylimide (19 mg, 0.028 mmol) and 50 μL diisopropylethylamine were added. The resulting solution was stirred under argon atmosphere for 20 hrs. After removing solvent and base by vacuum, the crude obtained was washed with both CH2Cl2 and, water and subsequently crystallized from MeOH. The desired 2-deoxyglucose conjugate (5) was obtained (8 mg). The filtrate was further concentrated and purified by silica gel plate chromatography (10% MeOH in CH2Cl2) to yield 4 mg of product. Thus, the total yield for 5 was 50% (12 mg). UV-vis in DMSO λmax: 366 nm (ε: 5.3×105), 419 (1.4×104), 550 (2.4×104), 648 (8.0×103) and 705 (5.2×104). Mass calcd for C44H53N7O9S: 878.3523 (M+Na)+; found by HRMS; 878.3542 (M+Na)+. 1H NMR (DMSO-d-6, δ ppm): 9.27, 9.16 and 8.85 (each s, 1H, for 10, 5 and 20-H), 8.01 (dd, 1H), 7.80 (br, 1H), 6.55 (br, 1H), 6.33 (d, 1H), 6.12 (d, 1H), 5.24-4.21 (9H), 3.80-3.40 (13H), 2.90 (s, 3H), 2.60 (m, 1H), 2.50-2.30 (m, 2H), 2.08 (m, 2H), 1.8 (m, 1H), 1.72 (d, 3H), 1.41 (t, 3H), −0.61 and −0.67 (each s, 1H, 2×NH).
- Bacteriopurpurin-18-N-3′-(BOC-amino)propylimide, BChlPP-BOC (7): Bacteriopurpurin-18 methyl ester (6) (100 mg, 0.186 mmol) and tert-Butyl N-(3-aminopropyl)-carbamate (250 mg, 1.44 mmol) were dissolved in benzene (7 mL). The solution was refluxed at 78° C. under argon atmosphere for 48 hrs. After removing solvent, the residue so obtained was purified by silica gel column chromatography with 5% MeOH in CH2Cl2 to afford the title compound in 18% yield (24 mg). UV-vis in CH2Cl2 λmax: 364 nm (ε: 8.4×104), 414 (4.2×104), 544 (3.1×104), 739 (7.6×103) and 820 (6.3×104). Mass calcd for C42H52N6O7: 752.4 (M); found by ESI-MS: 775.8 (M+Na)+. 1H NMR (CDCl3, δ ppm): 9.23, 8.80 and 8.62 (each s, 1H, for 5, 10 and 20-H), 5.62 (br, 1H, —NHBoc), 5.24 (m, 1H), 4.52 (m, 2H), 4.28 (m, 2H), 4.09 (m, 1H), 3.69, 3.59, 3.54 and 3.17 (each s, 3H), 3.31 (m, 2H), 2.71 (m, 1H), 2.37 (m, 3H), 2.15 (m, 2H), 2.10-1.90 (m, 2H), 1.81 (d, 3H), 1.72 (d, 3H), 1.50 (s, 9H), 1.11 (t, 3H), −0.46 and −0.68 (each s,
1H 2×NH). - Bacteriopurpurin-18-N-3′-(amino)propylimide, BChlPP-NH2 (8): The BOC derivative of bacteriopurpurinimide (24 mg, 0.032 mmol) was dissolved in TFA (2 mL). The solution was stirred at room temperature under argon atmosphere for 1 hr. After removing TFA by vacuum, the residue was redissolved in CH2Cl2 (40 mL), and washed with NaHCO3 (20 mL) and water (2×30 mL). The organic layer was dried over anhydrous Na2SO4. Removing solvent generated the title compound in 86% yield (18 mg). UV-vis in CH2Cl2 λmax: 365 nm (ε: 8.7×104), 416 (5.6×104), 547 (3.4×104), 736 (9.5×103) and 822 (6.5×104). Mass calculated for C37H44N6O5: 652.3; found by ESI-MS; 675.3 (M+Na)+. 1H NMR (CDCl3, δ ppm): 9.23, 8.80 and 8.63 (each s, 1H, 5-H; 10-H and 20-H), 5.27 (m, 1H), 4.54 (m, 2H), 4.28 (m, 2H), 4.09 (m, 1H), 3.69, 3.58, 3.55 and 3.17 (each s, 3H), 2.95 (m, 2H), 2.69 (m, 1H), 2.33 (m, 4H), 2.10-1.90 (m, 3H), 1.80 (d, 3H), 1.72 (d, 3H), 1.10 (t, 3H), −0.49 and −0.71 (each s, 1H, 2×NH).
- Bacteriopurpurin-18-N-3′-(isothiocyanate)propylimide, BChlPP-NCS (9): Amino derivatives of bacteriopurpurinimide (18 mg, 0.027 mmol) and 1,1′-thiocarbonyldiimidazole (5.3 mg, 0.0298 mmol) were dissolved in CH2Cl2 (2 mL). The solution was stirred at room temperature under argon atmosphere for 20 hrs. After removing solvent, the residue was purified by silica gel plate chromatography with 2% MeOH in CH2Cl2 to obtain the desired product in 75% yield (14 mg). UV-vis in CH2Cl2 λmax: 365 nm (ε: 8.4×104), 416 (4.8×104), 547 (3.5×104), 736 (9.0×103) and 822 (6.3×104). Mass calculated for C38H42N6O5SNa: 117.2835; found by HRMS; 717.2823 (M+Na+). 1H NMR (CDCl3, δ ppm): 9.23, 8.80 and 8.63 (each s, 1H, for 5, 10 and 20-H), 5.24 (d, 1H), 4.60 (t, 2H), 4.29 (m, 2H), 4.09 (m, 1H, 18-H), 3.85 (t, 2H), 3.69, 3.58, 3.55 and 3.17 (each s, 3H), 2.71 (m, 1H), 2.40 (m, 5H), 2.06 (m, 2H), 1.81 (d, 3H), 1.72 (d, 3H), 1.11 (t, 3H), −0.44 and −0.67 (each s, 1H, 2×NH).
- Preparation of 2-deoxyglucose conjugate of Bacteriopurpurin-18-N-3′-(isothiocyanate)-propylimide, BChlPP-2DG (10): D-Glucosamine hydrochloride (10 mg, 0.046 mmol) was added to a solution of sodium methoxide (2.5 mg, 0.046 mmol) in DMSO (2 mL). After stirring for 2 hrs, isothiocyanate containing bacteriopurpurinimide (16 mg, 0.023 mmol) and diisopropylethylamine (30 μL) were added and allowed to react for 18 h to form the conjugate. After removing the solvent, the crude so obtained was purified by silica gel plate chromatography with 20% MeOH in CH2Cl2. The desired conjugate (10) was obtained in 15% yield (3 mg). UV-vis in DMSO λmax: 365 nm (e: 8.4×104), 416 (7.5×104), 550 (2.9×104), 728 (2.5×104) and 821 (3.2×104). Mass calcd for C44H53N7O9S: 896.3629 (N+Na)+; found by HRMS; 896.3671 (M+Na)+.
- Bacteriochlorin e6-13-carboxy-N-3′-(BOC-amino)propylamide, BChlE6-BOC (12): Bacteriopheophorbide α methyl ester, 11 (625 mg, 1 mmol) was dissolved in chloroform (50 mL) and tert-butyl N-(−3-aminopropyl)-carbamate (380 mg, 2.18 mmol) was dissolved in 15 mL benzene. The mixture was refluxed at 78° C. under argon atmosphere for 48 h. After removing solvent, the crude residue was purified by silica gel column chromatography with 5% acetone in dichloromethane. The desired product was obtained in 70% yield (561 mg), UV-vis in CH2Cl2 λmax: 358 nm (ε: 2.23×104), 520 (0.5×104), 754 (1.98×104), Emission λmax (CH2Cl2): 758 nm, Mass. calcd for C39H50N6O6 798.43 found by ESI-MS; 799.43 (M+1)+ 1H NMR (CDCl3, δ ppm) 9.33, 8.71 and 8.58 (each, s, 1H, for 5, 10, 20-H), 6.96 (s, 1H,), 4.33 (m, 2H), 4.05 (m, 2H), 3.87 (s, 3H), 3.63 (s, 3H), 3.50 (s, 3H), 3.46 (s, 3H), 3.17 (s, 3H), 2.54 (m, 2H), 2.25-2.09 (m, 4H), 1.82 (d, 3H), 1.79 (d, 3H), 1.14 (t, 3H), 0.49 and 0.10 (each, s, 2×NH).), 13C NMR (CDCl3) 198.83, 173.71, 169.62, 168.34, 169.77, 169.75, 163.86, 158.12, 148.29, 139.27, 138.51, 137.03, 136.51, 133.46, 128.83, 121.54, 108.20, 99.83, 97.86, 96.00, 64.55, 55.14, 53.01, 51.89, 50.79, 49.90, 49.06, 33.53, 31.14, 30.37, 30.12, 29.49, 29.45, 28.54, 23.85, 23.38, 13.92, 12.01, 11.01.
- Bacteriochlorin e6-13-carboxy-N-3′-(amino)propylamide (BChlE6-NH2, 13) and Bacteriochlorin e6-13-carboxy-N-3′-(isothiocyanate)propylamide BChlE6-NCS, 14): BChlE6-BOC (400 mg, 0.5 mmol) was dissolved in 6 mL TFA. The mixture was stirred at room temperature under argon atmosphere. One hour later, TFA was removed by vacuum. The crude residue was diluted with 40 mL CH2Cl2, washed once with 30 mL NaHCO3 and twice with 30 mL water after which the organic layer was dried over anhydrous Na2SO4. After removing solvent, BChlE6-NH2 was obtained (300 mg, 0.43 mmol) at an 86% yield. UV-vis in CH2Cl2 λmax: 358 nm (ε: 2.23×104), 520 (0.5×104), 752 (1.98×104), Emission λmax (CH2Cl2): 770 nm, Mass. calculated for C39H50N6O6 698.38 found by ESI-MS; 698.26.
- BChlE6-NH2 was then used directly for the next reaction step without further purification. BChl-NH2 (300 mg, 0.43 mmol) and 1,1′-thiocarbonyldiimidazole (71.3 mg) were dissolved in 20 mL CH2Cl2. The reaction mixture was subsequently refluxed at 40° C. under argon atmosphere for 3 h, and the solvent was removed. The residue was purified by silica gel chromatography with 2% MeOH—CH2Cl, and 95 mg of BChlE6-NCS was collected (yield 75%). UV-vis in CH2Cl2 λmax: 358 nm (ε: 2.23×104), 520 (0.5×104), 754 (1.98×104), Emission λmax (CH2Cl2): 758 nm, Mass. calcd for C39H50N6O6 798.43 found by ESI-MS; 799.43 (M+1)+ 1H NMR (CDCl3, δ ppm) 8.99, 8.50 and 8.43 (each, s, 1H, for 10, 5 and 20-H), 6.10 (s, 1H,), 4.33 (m, 2H, 4.05 (m, 2H), 3.87 (s, 3H), 3.63 (s, 3H), 3.50 (s, 3H), 3.46 (s, 3H), 3.17 (s, 3H), 2.54 (m, 2H), 2.25-2.09 (m, 4H), 1.82 (d, 3H), 1.79 (d, 3H), 1.14 (t, 3H), −0.44 and −0.67 (each, s, 2×NH), 13C NMR (CDCl3, δ ppm) 198.83, 173.71, 169.62, 168.34, 169.77, 169.75, 163.86, 158.12, 148.29, 139.27, 138.51, 137.03, 136.51, 133.46, 128.83, 121.54, 104.37, 98.51, 97.63, 96.78, 57.48, 53.24, 52.45, 51.84, 48.23, 46.98, 43.21, 37.97, 37.88, 33.39, 31.23, 30.22, 30.13, 29.50, 23.80, 23.34, 13.91, 12.01, 11.01.
- Preparation of 2-deoxyglucose conjugate of bacteriochlorin e6-isothiocyanate, BChlE6-2DG (15): D-Glucosamine hydrochloride (23.5 mg, 0.11 mmol) was added to a solution of sodium methoxide (5.9 mg, 0.11 mmol) in DMF (5 mL). After stirring for 2 h, BChlE6-NCS (40 mg, 0.054 mmol) and N,N-diisopropylethylamine (71 μL) were added and allowed to react for 18 h to from the conjugate. After removing the solvent, the crude obtained was purified by silica gel plate chromatography with 20% MeOH in CH2Cl2. The desired conjugate was obtained in 60% yield (30 mg). Uv-vis in MeOH λmax: 358 nm (ε: 2.23×104), 520 (0.5×104), 754 (1.98×104), Emission λmax (MeOH): 768 nm, Mass. calcd for C45H59N7O11S+Na: 942.4047, found by high resolution MS: 942.4081 (<5 ppm). 1H NMR (CDCl3, δ ppm) 9.24, 8.74 and 8.61 (each, s, 1H, for 10, 5, 20-H), 5.34 (d, 1H), 5.11 (d, 1H), 4.31 (m, 1H), 4.26 (m, 1H), 4.17 (m, 2H), 4.03 (brs. 8H), 3.87 (m, 4H), 3.74 (m, 2H), 3.72 (s, 3H), 3.58 (s, 3H) 3.57 (s, 3H), 3.34 (s, 3H, 3.18 (s, 3H), 2.58 (m, 2H), 2.40-2.03 (m, 8H), 1.82 (d, 3H), 1.79 (m, 2H), 1.59 (d, 3H), 1.05 (t, 3H), −0.61 and −0.67 (each s, 1H, 2×NH), 13C NMR (CDCl3) 198.83 (31 C), 173.71 (173 C), 169.62 (152 C), 168.34 (131 C), 169.77 (1 C), 169.75 (133 C), 163.86 (4 C), 158.12 (14 C), 148.29 (16 C), 139.27 (11 C), 138.51 (6 C), 137.03 (9 C), 136.51 (12 C), 133.46 (13 C), 128.83 (3 C), 121.54 (2 C), 108.20 (15 C), 99.83 (5 C), 97.86 (10 C), 96.00 (20 C), 64.55 (132 C), 55.14 (8 C), 53.01 (134 C), 51.89 (174 C), 50.79 (17 C), 49.90 (18 C), 49.06 (7 C), 33.53 (32 C), 31.14 (172 C), 30.37 (81 C), 30.12 (171 C), 28.54 (137, 138, 139 C, 3C) 23.85 (71 C), 23.38 (181 C), 13.92 (21 C), 12.01 (121 C), 11.01 (82 C). HPLC retention time: 30.1 min (using 0.1M TEAA and CH3CN as HPLC eluent, from 10% CH3CN to 90% CH3CN for 45 min).
- In vivo NIR optical imaging system: To image and localize subsurface fluorochrome labeled tumors, an NIR imaging system utilizing diffusion photons (Patterson, M. S.; Chance, B.; Wilson, B. C., Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. Applied Optics 1989, 28, 2331-2336.
- Fishkin, J. B.; Gratton, E., Propagation of photon-density waves in strongly scattering media containing an absorbing semi-infinite plane bounded by a straight edge. Journal of the Optical Society of
America A 1993, 10, 127-140.) has been developed. The in vivo fluorescence optical imaging system consists of a pair of laser diodes operating at 780 nm. The light intensities are modulated by 50 MHz sinusoidal radio frequency waves, but with a 180° phase difference between them. Detection sensitivity and localization accuracy are enhanced through phase cancellation techniques. (Chance, B.; Kang, K.; He, L.; Weng, J.; Sevick-Muraca, E. M., Highly sensitive object location in tissue models with linear in-phase and anti-phase multi-element optical arrays in one and two dimensions. Proceedings of the National Academy of Sciences USA 1993, 90, 3423-3427. - Chance, B.; Kang, K.; He, L.; Liu, H.; Zhou, S., Precision localization of hidden absorbers in body tissues with phased-array optical systems. Review of Scientific Instruments 1996, 67, 4324-44332.
- Intes, X.; Chen, Y.; Li, X. D.; Chance, B., Detection limit enhancement of fluorescent heterogeneities in turbid media by dual-interfering excitation. Applied Optics 2002, 41, (19), 3999-4007.) The excitation photons are delivered to the imaging chamber filled with highly scattering medium (Intralipid® and ink) through fiber optics. The tumor-bearing animal injected with BChlPP-2DG is immersed inside the imaging chamber, and the tumor is placed within 1.5 cm from the outside surface. A 3-mm-in-diameter fiber bundle collects the fluorescence signal from the fluorophore taken by in the tumor. An interference filter at 830 nm is used to select the emitted fluorescent photons. The fluorescence signal is then detected by the photomultiplier tube (PMT) and demodulated by the 50 MD receiver to obtain the amplitude and phase information. The imaging probe consists of two source fibers with a separation of 2 cm and a detection fiber bundle with equal distance (4 cm) from each source. The source and detector fibers can be scanned in tandem under the control of a stepper motor. After finishing one axial scan, the probe can be rotated to another angle to perform another axial scan. Multiple radial scans in different directions can be acquired for object localization. (Chen, Y.; Mu, C. P.; Intes, X.; Blessington, D.; Chance, B., Near-infrared phase cancellation instrument for fast and accurate localization of fluorescent heterogeneity. Review of Scientific Instruments 2003, 74, (7), 3466-3473.) The optical imaging probe is placed on the surface of the imaging chamber and scanned through a 5-cm-in-diameter area for subsurface localization of fluorescence enhanced tumor. Two-dimensional localization of the subsurface fluorochrome is obtained by fitting the experimental data to the analytical solutions and searching for the minimum of the probability function χ2. (Chen, Y.; Zheng, G.; Zhang, Z. H.; Blessington, D.; Zhang, M.; Li, H.; Liu, Q.; Zhou, L.; Intes, X.; Achilefu, S.; Chance, B., Metabolism-enhanced tumor localization by fluorescence imaging: in vivo animal studies. Optics Letters 2003, 28, (21), 2070-2072).
- Results and Discussion
- In order to effectively functionalize bacteriochlorophylls utilized to label biomolecules, the reactive functional groups that are added should not only be stable enough for prolonged storage ability but should also exhibit high labeling efficiencies with minimal side reactions; ultimately, they must produce a stable covalent bond. Isothiocyanate has been widely used for coupling with primary and secondary amines of biologically important molecules; (Flanagan, J. H.; Khan, S. H.; Menchen, S.; Soper, S. A.; Hammer, R. P., Functionalized tricarbocyanine dyes as near-infrared fluorescent probes for biomolecules.
Bioconjugate Chemistry 1997, 8, (5), 751-756.) thus, it became the labeling functionality of choice. Pandey et al. have shown that unstable bacteriochlorophyll a analogs containing a five-member isocyclic ring can be converted to the related bacteriochlorin bearing either a fused six-member anhydride or imide ring systems; these derivatives are referred to as bacteriopurpurin-18 (BChlPP) and bacteriopurpurinimide analogs, respectively. (Kozyrev, A. N.; Zheng, G.; Zhu, C. F.; Dougherty, T. J.; Smith, K. M.; Pandey, R. K., Syntheses of stable bacteriochlorophyll-a derivatives as potential photosensitizers for photodynamic therapy. Tetrahedron Letters 1996, 37, (36), 6431-6434.) The latter is particularly interesting because it presents a unique opportunity to introduce the isothiocyanate labeling functionality at the fused imide ring for convenient conjugation to tumor-homing molecules. To develop an effective synthetic strategy, model studies were performed by using a less expensive substrate, purpurin-18 methyl ester, 1 (Zheng, G.; Potter, W. R.; Camacho, S. H.; Missert, J. R.; Wang, G. S.; Bellnier, D. A.; Henderson, B. W.; Rodgers, M. A. J.; Dougherty, T. J.; Pandey, R. K., Synthesis, photophysical properties, tumor uptake, and preliminary in vivo photosensitizing efficacy of a homologous series of 3-(1′-alkyloxy)ethyl-3-devinaylpurpurin-18-N-alkylimides with variable lipophilicity. Journal of Medicinal Chemistry 2001, 44, (10), 1540-1559.). As shown inScheme 1, reaction of 1 with tert-butyl N-(3-aminopropyl)-carbamate at reflux temperature gave the corresponding BOC-protected amino containing purpurinimide (PP-BOC, 2) in high yield. Upon TFA cleavage of the BOC protecting group, purpurin-18-N-3′-(amino)propylimide, 3, was obtained. The amino functionality in 3 was her converted to the desired isothiocyanate labeling moiety incompound 4 by reacting with 1,1′-thiocarbonyldiimidazole. The overall yield of this three-step process was about 50%. To test the utility of this functionalized model compound, a 2-deoxyglucose moiety was selected as the tumor-homing molecule via the glucose transporter (GLUT) pathway. (Zhang, M.; Zhang, Z. H.; Blessington, D.; Li, H.; Busch, T. M.; Madrak, V.; Miles, J.; Chance, B.; Glickson, J. D.; Zheng, G., Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters. Bioconjugate Chemistry 2003, 14, (4), 709-714.) Thus, following a procedure we reported earlier, (Zhang, M.; Zhang, Z. H.; Blessington, D.; Li, H.; Busch, T. M.; Madrak, V.; Miles, J.; Chance, B.; Glickson, J. D.; Zheng, G., Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters. Bioconjugate Chemistry 2003, 14, (4), 709-714) isothiocyanate containing purpurin-18 was reacted with D-glucosamine to yield the desiredconjugate 5 in 50% yield. - After model reactions, bacteriopurpurin-18-N-3′-(amino)propylimide BChlPP-NH2, 8) was synthesized from bacteriopurpurin-18-N-3′-(BOC-amino)propylimide (BChlPP-BOC, 7) and converted successfully to bacteriopurpurin-18-N-3′-(isothiocyanate)propylimide (BChlPP-NCS, 9) as shown in
Scheme 1. However, compared to model reactions, the overall yield of BChlPP-NCS from BChlPP dropped from 50% to 10% with BChlPP-BOC formation as the yield-limiting step. The conversion of BChlPP to its corresponding BChlPP-BOC, BChlPP-NH2 and BChlPP-NCS was clearly demonstrated by their NMR spectra. As shown inFIG. 11 , the 5.62 and the 3.31 ppm peaks observed in the BChlPP-BOC spectrum (shown partially) belonged to the N—H proton and the CH2N protons adjacent to the BOC protection group, respectively. Cleavage of the BOC group led to the disappearance of the N—H peak and the upfield shift of the CH 2N resonance to 2.95 ppm. Further conversion of BChlPP-NH2 to BChlPP-NCS shifts the above mentioned CH 2 resonance downfield to 3.85 ppm. - Next, a 2-deoxyglucose moiety was conjugated to BChlPP via the isothiocyanate coupling strategy to form the desired BChlPP-2DG, 10. Again, the coupling yield dropped significantly from 50% to 15% compared to the model reaction. These low yield steps are presumably caused by undesirable byproduct formation (e.g., the formation of 12-hydroxymethyl derivative of BChlPP-2DG) under basic conditions. Due to the limited amount of the final conjugate, a satisfactory NMR spectrum for
compound 10 was not obtained. Nevertheless, the structure and the purity of BChlPP-2DG were confirmed by high resolution mass spectrometry and reverse phase HPLC (FIG. 12 a), respectively. Based on the absorption and emission spectra of this conjugate (FIG. 12 b), a preliminary study was performed to evaluate this agent in vivo in animal models; it proved to show great promise as a tumor-targeting NIR optical contrast agent (details described in a later section). However, due to the low yield, it is not practical to undertake systematic evaluation of this new conjugate. - To improve the feasibility of using BChl-based bioconjugates for cancer detection and treatment, we explored another synthetic strategy to functionalize BChl. Bacteriopheophorbide a methyl ester 11 was first reacted with tert-butyl N-(-3-aminopropyl)-carbamate to form a single regioisomer, bacteriochlorin e6-13-carboxy-N-3′-(BOC-amino)propylamide, BChlE6-BOC (12). This intermediate was then converted to its corresponding amino- and isothiocyanate-containing BChl (BChlE6-NH2 13 and BChlE6-NCS 14) following the strategy described earlier. Compared with the previous procedure (10% overall yield from BChlPP to BChlPP-NCS, see Scheme 2), the new synthetic route from bacteriopheophorbide a methyl ester to BChlE6-NCS shown in
Scheme 3 has the overall yield of 45%. Considering that bacteriopheophorbide a methyl ester is the precursor of BChlPP, the actual yield improved is five- to ten-folds. Furthermore, the yield of the final conjugation step to produce bacteriochlorin e6 2-deoxyglucosamide BChlE6-2DG, 15) also increased from 15% to 60% compared to that of BChlPP-2DG. The structure of BChlE6-2DG was confirmed by 1H, 13C NMR and high resolution mass spectrometry. The purity of BChlE6-2DG was 99% by RP-HPLC.FIG. 13 shows the HPLC chromatogram and the absorption spectra of the final conjugate. - In Vivo Tumor Detection by Optical Imaging. One of the 2-deoxyglucose conjugates of bacteriochlorophyll (BChlPP-2DG) was imaged in vivo on an animal model of human cancer. As shown in
FIG. 14 , the experiment was setup to have the animal submerged up to the neck in the Intralipid® medium that simulates the scattering fatty tissues surrounding the tumor. The imaged animals are athymic nu/nu mice with implanted AR42J tumors (pancreatic acinar carcinoma) on the right thigh and injected with BChlPP-2DG after 12 hours of fasting. The imaging was performed on the anesthetized mice 3.5 hours after the injection of the contrast agent. Usually 200 μL of the contrast agents. The amount of injected contrast agents is usually 200 μL at a concentration of 1 mg/mL. The scattering media has similar optical properties as human breast tissue for studies of breast cancer models, and is maintained at physiological temperature (−37° C.). The tumor cells are hyper-metabolic compared with normal cells; consequently, they take up more glucose contrast agents into the tumor cells than nearby normal tissues. The mouse is kept alive throughout the experiment. The optical imaging probe is placed on the surface of the imaging chamber and scanned through a 5-cm-in-diameter area for subsurface localization of fluorescence enhanced tumor.FIG. 15 a is the image obtained from BChl-2DG treated animals. The tumor region is enhanced. The localization of the tumor at a depth of 1.5 cm under the surface is accurately resolved, with a location error of 3.0±0.6 mm. For comparison,FIG. 15 b shows the image of the mouse tumor following tail-vein injection of ICG. There is no significant enhancement in the tumor region, suggesting that the ICG could not provide high contrast between tumor and the normal tissue after 3.5 hours. This result is in agreement with the non-tumor-specificity of ICG and the depletion of ICG from the circulation system rapidly by the liver. (Achilefu, S.; Dorshow, R. B.; Bugaj, J. E.; Rajagopalan, R., Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Investigative Radiology 2000, 35, 479-485).FIG. 15 c illustrates a negative control animal without the injection of the contrast agents; under these conditions the fluorescence phased array system does not detect the signals from the tumor. - The synthesis of two novel functionalized bacteriochlorophylls dyes is described. These new NIR dyes containing isothiocyanate functional groups are reactive toward primary amines; thus, they can be conjugated to biologically important compounds such as tumor-specific homing molecules. Compared with functionalized dyes derived from bacteriopurpurimides, dyes based on the bacteriochlorin e6 moiety are produced in much better yield (5- to 10-fold), though the former has longer wavelength absorption and fluorescence emission (ex: 819 nm; em: 826 nm) than the latter (ex: 752 nm; em: 766 nm). Both of these functionalized bacteriochlorophylls showed successful conjugation to the glucose transporter-homing 2-deoxyglucose moiety. BChlPP-2DG was further tested in vivo in animal tumors using a phase array NIR optical imaging system and showed promise as a the tumor-targeting agent for the detection and treatment of subsurface cancers.
Claims (19)
1-36. (canceled)
38. The conjugate of claim 37 , wherein said linker group, L, is selected from the group consisting of a covalent bond, —NH—, -peptide-, -nucleic acid-, —O—, (CH2)r—O—, —NH—CH2—CH2—NH—, —NH—CH(COOH)—CH2—NH—, —NH—CH2—CH(COOH)—NH—, —NH—CH2—CH2—CH2—NH, —O—(CH2)r—NH—, S—(CH2)r—NH—, —S—(CH2)r—C(O)—, —NH—CH2—C(O)—, —O—CH2—CH2—O—CH2—CH2—O, —NH—NH—C(O)—CH2—, —NH—C(CH2)2—C(O)—, and —NH—NH—C(O)—(CH2)r—C(O)NH—N═, wherein r, in each instance, is from 2-5.
39. The conjugate of claim 38 , wherein said linker group is susceptible to cleavage by cytosolic enzymes.
40. The conjugate of claim 39 , wherein said linker group is a peptide consisting of from about 1 to about 6 amino acids.
41. A method of treating tumor disease in an animal, comprising administering the compound of claim 37 to an animal in need thereof to treat the tumor disease of the animal.
42. A method of inhibiting the growth of a cancer cell comprising: (a) contacting said cancer cell with the conjugate of claim 37 and
(b) exposing said cancer cell to an effective amount of artificial irradiation.
43. The method of claim 42 , wherein said cancer cell is selected from the group consisting of breast, lung, pancreas, bladder, ovarian, testicular, prostate, liver, retinoblastoma, Wilm's tumor, adrenocarcinoma or melonoma.
44. The method of claim 42 , wherein said artificial irradiation is selected from the group consisting of artificial ultraviolet, infrared (IR), gamma-irradiation, x-ray and visible light.
45. The method of claim 44 , wherein said artificial irradiation is IR.
46. The method of claim 44 , wherein said IR is near-infrared (NIR).
47. The method of claim 42 , wherein said artificial irradiation is applied at the maximum absorption of the photosensitizer.
48. The method of claim 42 , wherein said artificial irradiation is applied about 5 minutes to about 3 hours after administering the conjugate of claim 38 .
49. The method of claim 42 , wherein said artificial irradiation is applied about 10 to about 60 minutes after administering the conjugate of claim 38 .
50. The method of claim 42 , wherein said artificial irradiation is applied for about 5 seconds to about 60 minutes.
51. The method of claim 42 , wherein said artificial irradiation is applied for about 1 minute to about 45 minutes.
52. The method of claim 42 , wherein said artificial irradiation is applied for about 10 to about 30 minutes.
53. A pharmaceutical composition comprising the conjugate of claim 37 and a pharmaceutically acceptable carrier.
54. A method for the treatment of cancer in a subject comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 53 to a subject in need thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/027,014 US20080269112A1 (en) | 2003-06-09 | 2008-02-06 | Antineoplastic Agents Targeted via Glut Transporters |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47664803P | 2003-06-09 | 2003-06-09 | |
US53728204P | 2004-01-16 | 2004-01-16 | |
US54070004P | 2004-01-30 | 2004-01-30 | |
US54824004P | 2004-02-27 | 2004-02-27 | |
US10/560,075 US7943586B2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
PCT/US2004/018143 WO2004110255A2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
US12/027,014 US20080269112A1 (en) | 2003-06-09 | 2008-02-06 | Antineoplastic Agents Targeted via Glut Transporters |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/018143 Division WO2004110255A2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
US10/560,075 Division US7943586B2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080269112A1 true US20080269112A1 (en) | 2008-10-30 |
Family
ID=33556646
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/560,075 Expired - Fee Related US7943586B2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
US12/027,014 Abandoned US20080269112A1 (en) | 2003-06-09 | 2008-02-06 | Antineoplastic Agents Targeted via Glut Transporters |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/560,075 Expired - Fee Related US7943586B2 (en) | 2003-06-09 | 2004-06-09 | Antineoplastic agents targeted via glut transporters |
Country Status (2)
Country | Link |
---|---|
US (2) | US7943586B2 (en) |
WO (1) | WO2004110255A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017044445A1 (en) * | 2015-09-09 | 2017-03-16 | On Target Laboratories, LLC | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer |
US20180011346A1 (en) * | 2016-07-05 | 2018-01-11 | Nanoco Technologies Ltd. | Probe for targeting and manipulating mitochondrial function using quantum dots |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003225763A1 (en) * | 2002-03-11 | 2003-09-29 | Visen Medical, Inc. | Optical imaging probes |
CA2611735A1 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of Colorado | Therapeutic bifunctional compounds |
US20080275432A1 (en) * | 2006-05-11 | 2008-11-06 | Ceramoptec Industries, Inc. | Photodynamic foam composition and sclerosis treatment |
EP2244741B1 (en) | 2008-01-18 | 2015-03-25 | VisEn Medical, Inc. | Fluorescent imaging agents |
WO2009105230A2 (en) | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
WO2009121055A1 (en) * | 2008-03-28 | 2009-10-01 | Georgia Tech Research Corporation | Reduced dye probes for the detection of radical oxygen species |
WO2009123735A1 (en) * | 2008-04-04 | 2009-10-08 | The Regents Of The University Of California | Use of functionalized magnetic nanoparticles in cancer detection and treatment |
EP2313095A4 (en) | 2008-07-14 | 2013-04-17 | Univ Colorado | Methods and products for treating proliferative diseases |
US8450090B2 (en) | 2009-10-06 | 2013-05-28 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for promoting fatty acid production in plants |
WO2012166792A1 (en) * | 2011-05-31 | 2012-12-06 | North Carolina State University | Bacteriochlorin imides |
JP6118808B2 (en) | 2011-10-31 | 2017-04-19 | ザ メソジスト ホスピタル リサーチ インスティテュート | Compounds comprising a MAO targeting / search moiety for treating human glioma |
CN107722075A (en) * | 2017-10-09 | 2018-02-23 | 大连理工大学 | A kind of chlorin glucoside compounds and preparation method and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622936A (en) * | 1988-10-20 | 1997-04-22 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Tumor inhibiting saccharide conjugates |
US6489302B1 (en) * | 1995-07-05 | 2002-12-03 | Deutches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Saccharide conjugates |
US6548484B1 (en) * | 2000-04-12 | 2003-04-15 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
US20030181393A1 (en) * | 2000-05-01 | 2003-09-25 | Lampidis Theodore J. | Cancer treatment including glycolytic inhibitors |
US20040029815A1 (en) * | 2002-03-29 | 2004-02-12 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20040152665A1 (en) * | 2003-01-31 | 2004-08-05 | Anastassiades Tassos P. | Amelioration of decreased weight and growth by n-acylated glucosamines |
US6989140B2 (en) * | 2001-12-21 | 2006-01-24 | Threshold Pharmaceuticals, Inc. | Methods for cancer imaging |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT99864B (en) | 1990-12-21 | 1999-06-30 | Schering Ag | METHOD FOR PREPARING NEW PHARMACEUTICAL COMPOSITIONS CONTAINING QUISQUALATE RECEPTOR ANTAGONISTS |
US6849607B2 (en) * | 2001-05-09 | 2005-02-01 | Health Research, Inc. | Galectin recognized photosensitizers for photodynamic therapy |
EP1509229B1 (en) | 2002-05-28 | 2009-09-23 | Pace- Asciak, Cecil R. | Compositions comprising hepoxilin analogs and their use in the treatment of cancer |
JP2006515622A (en) | 2003-01-13 | 2006-06-01 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | Carbohydrate conjugates to prevent the abuse of controlled substances |
-
2004
- 2004-06-09 WO PCT/US2004/018143 patent/WO2004110255A2/en active Application Filing
- 2004-06-09 US US10/560,075 patent/US7943586B2/en not_active Expired - Fee Related
-
2008
- 2008-02-06 US US12/027,014 patent/US20080269112A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622936A (en) * | 1988-10-20 | 1997-04-22 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Tumor inhibiting saccharide conjugates |
US6489302B1 (en) * | 1995-07-05 | 2002-12-03 | Deutches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Saccharide conjugates |
US6548484B1 (en) * | 2000-04-12 | 2003-04-15 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
US20030181393A1 (en) * | 2000-05-01 | 2003-09-25 | Lampidis Theodore J. | Cancer treatment including glycolytic inhibitors |
US6989140B2 (en) * | 2001-12-21 | 2006-01-24 | Threshold Pharmaceuticals, Inc. | Methods for cancer imaging |
US20040029815A1 (en) * | 2002-03-29 | 2004-02-12 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20040152665A1 (en) * | 2003-01-31 | 2004-08-05 | Anastassiades Tassos P. | Amelioration of decreased weight and growth by n-acylated glucosamines |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017044445A1 (en) * | 2015-09-09 | 2017-03-16 | On Target Laboratories, LLC | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer |
WO2017044443A1 (en) * | 2015-09-09 | 2017-03-16 | On Target Laboratories, LLC | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer |
US10676487B2 (en) | 2015-09-09 | 2020-06-09 | On Target Laboratories, LLC | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer |
US20180011346A1 (en) * | 2016-07-05 | 2018-01-11 | Nanoco Technologies Ltd. | Probe for targeting and manipulating mitochondrial function using quantum dots |
Also Published As
Publication number | Publication date |
---|---|
WO2004110255A3 (en) | 2005-10-27 |
US20060171893A1 (en) | 2006-08-03 |
WO2004110255A2 (en) | 2004-12-23 |
US7943586B2 (en) | 2011-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080269112A1 (en) | Antineoplastic Agents Targeted via Glut Transporters | |
EP1517684B1 (en) | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy | |
EP0213272B1 (en) | New tetrapyrrole polyaminomonocarboxylic acid therapeutic agents | |
US20200094069A1 (en) | Water soluble anionic bacteriochlorophyll derivatives and their uses | |
US7252815B2 (en) | Pathological tissue detection and treatment employing targeted benzoindole optical agents | |
Di Stasio et al. | The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin | |
EP1246826B1 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
WO1997032885A1 (en) | Synthesis of isoimide of chlorins and bacteriochlorins and their use for diagnosis and treatment of cancer | |
EP1781170B1 (en) | Adduct of fluorescent dye and tumor avid tetrapyrrole | |
Grin et al. | Novel bacteriochlorophyll-based photosensitizers and their photodynamic activity | |
WO2003055887A1 (en) | Conjugated porphyrin, chlorin or bacteriochlorin chromophore | |
KR101842633B1 (en) | Diagnostic or therapeutic composition of cancer which is activated by cathepsin B, and near-infrared imaging and phototherapy of tumor using the same | |
US20220194952A1 (en) | Tetrapyrrolic conjugates and uses thereof for imaging | |
Li et al. | NIR optical probes targeting glucose transporters | |
Ronchi | Photodynamic therapy in nanomedicine: synthesis and multidisciplinary characterization of squaraine sensitizers for theranostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR, MARY Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:047770/0260 Effective date: 20181206 |